UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


(Mark One)
☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 27,~~September 26, 2021


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number 1-5353

TELEFLEX INCORPORATED

(Exact name of registrant as specified in its charter)


Delaware						23-1147939
(State or other jurisdiction of incorporation or organization)						(I.R.S. employer identification no.)

550 E. Swedesford Rd., Suite 400 Wayne, PA 19087

(Address of principal executive offices and zip code)

(610) 225-6800

(Registrant’s telephone number, including area code)

(None)

(Former Name, Former Address and Former Fiscal Year,

If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $1.00 per share

TFX

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The registrant had ~~46,801,138~~46,844,950 shares of common stock, par value $1.00 per share, outstanding as of ~~July 27,~~October 26, 2021.

TELEFLEX INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED ~~JUNE 27,~~SEPTEMBER 26, 2021

TABLE OF CONTENTS

Page

PART I — FINANCIAL INFORMATION

Item 1:

Financial Statements (Unaudited):

Condensed Consolidated Statements of Income

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Changes in Equity

Notes to Condensed Consolidated Financial Statements

Item 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3:

Quantitative and Qualitative Disclosures About Market Risk

Item 4:

Controls and Procedures

PART II — OTHER INFORMATION

Item 1:

Item 1A:

Item 2:

Unregistered Sales of Equity Securities and Use of Proceeds

3031

Item 3:

Defaults Upon Senior Securities

3031

Item 4:

Mine Safety Disclosures

Item 5:

Item 6:

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


		Three Months Ended				Six Months Ended					Three Months Ended				Nine Months Ended
		June 27, 2021		June 28, 2020		June 27, 2021		June 28, 2020			September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
		(Dollars and shares in thousands, except per share)									(Dollars and shares in thousands, except per share)
Net revenues	Net revenues	$	713,473	$	567,034	$	1,347,398	$	1,197,676	Net revenues	$	700,251	$	628,301	$	2,047,649	$	1,825,977
Cost of goods sold	Cost of goods sold	315,917		288,662		605,315		585,680		Cost of goods sold	312,464		298,977		917,779		884,657
Gross profit	Gross profit	397,556		278,372		742,083		611,996		Gross profit	387,787		329,324		1,129,870		941,320
Selling, general and administrative expenses	Selling, general and administrative expenses	224,159		191,193		427,307		338,989		Selling, general and administrative expenses	205,194		171,673		632,501		510,662
Research and development expenses	Research and development expenses	33,283		29,364		63,230		56,760		Research and development expenses	31,816		29,218		95,046		85,978
Restructuring and impairment charges		11,494		19,005		19,492		20,351

Restructuring and impairment charges (credits)										Restructuring and impairment charges (credits)	959		(3,659)		20,451		16,692
Gain on sale of business										Gain on sale of business	(91,157)		—		(91,157)		—
Income from continuing operations before interest and taxes	Income from continuing operations before interest and taxes	128,620		38,810		232,054		195,896		Income from continuing operations before interest and taxes	240,975		132,092		473,029		327,988
Interest expense	Interest expense	16,171		15,682		32,969		31,121		Interest expense	11,989		16,652		44,958		47,773
Interest income	Interest income	(232)		(163)		(891)		(742)		Interest income	(215)		(214)		(1,106)		(956)
Loss on extinguishment of debt	Loss on extinguishment of debt	12,986		0		12,986		0		Loss on extinguishment of debt	—		—		12,986		—
Income from continuing operations before taxes	Income from continuing operations before taxes	99,695		23,291		186,990		165,517		Income from continuing operations before taxes	229,201		115,654		416,191		281,171
Taxes on income from continuing operations		16,412		11,848		28,840		22,922
Taxes (benefits) on income from continuing operations										Taxes (benefits) on income from continuing operations	29,695		(951)		58,535		21,971
Income from continuing operations	Income from continuing operations	83,283		11,443		158,150		142,595		Income from continuing operations	199,506		116,605		357,656		259,200
Operating (loss) income from discontinued operations		(46)		22		(47)		18
Tax (expense) benefit on operating loss from discontinued operations		(11)		9		(11)		7
(Loss) income from discontinued operations		(35)		13		(36)		11
Operating loss from discontinued operations										Operating loss from discontinued operations	(423)		(29)		(470)		(11)
Tax benefit on operating loss from discontinued operations										Tax benefit on operating loss from discontinued operations	(98)		(11)		(109)		(4)
Loss from discontinued operations										Loss from discontinued operations	(325)		(18)		(361)		(7)
Net income	Net income	$	83,248	$	11,456	$	158,114	$	142,606	Net income	$	199,181	$	116,587	$	357,295	$	259,193
Earnings per share:	Earnings per share:									Earnings per share:
Basic:	Basic:									Basic:
Income from continuing operations	Income from continuing operations	$	1.78	$	0.25	$	3.39	$	3.07	Income from continuing operations	$	4.26	$	2.51	$	7.66	$	5.58
Loss from discontinued operations	Loss from discontinued operations	0		0		(0.01)		0		Loss from discontinued operations	—		—		(0.02)		—
Net income	Net income	$	1.78	$	0.25	$	3.38	$	3.07	Net income	$	4.26	$	2.51	$	7.64	$	5.58
Diluted:	Diluted:									Diluted:
Income from continuing operations	Income from continuing operations	$	1.76	$	0.24	$	3.34	$	3.02	Income from continuing operations	$	4.20	$	2.46	$	7.54	$	5.48
Loss from discontinued operations	Loss from discontinued operations	0		0		(0.01)		0		Loss from discontinued operations	—		—		(0.01)		—
Net income	Net income	$	1.76	$	0.24	$	3.33	$	3.02	Net income	$	4.20	$	2.46	$	7.53	$	5.48
Weighted average common shares outstanding	Weighted average common shares outstanding									Weighted average common shares outstanding
Basic	Basic	46,741		46,442		46,719		46,412		Basic	46,810		46,530		46,749		46,451
Diluted	Diluted	47,433		47,242		47,420		47,237		Diluted	47,452		47,333		47,431		47,269

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)


		Three Months Ended				Six Months Ended				Three Months Ended				Nine Months Ended
		June 27, 2021		June 28, 2020		June 27, 2021		June 28, 2020				September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
		(Dollars in thousands)										(Dollars in thousands)
Net income	Net income	$	83,248	$	11,456	$	158,114	$	142,606		Net income	$	199,181	$	116,587	$	357,295	$	259,193
Other comprehensive income (loss), net of tax:	Other comprehensive income (loss), net of tax:										Other comprehensive income (loss), net of tax:
Foreign currency translation, net of tax of $1,002, $2,295, $404, and $(5,286) for the three and six months periods, respectively		6,080		17,654		(17,995)		(545)
Pension and other postretirement benefit plans adjustment, net of tax of $(390), $(404), $(903), and $(926) for the three and six months periods, respectively		1,298		1,345		2,909		3,034
Derivatives qualifying as hedges, net of tax of $39, $64, $72, and $436 for the three and six months periods, respectively		397		(1,095)		424		(4,912)
Other comprehensive income (loss), net of tax:		7,775		17,904		(14,662)		(2,423)
Foreign currency translation, net of tax of $(1,464), $6,957, $(1,060), and $1,671 for the three and nine months periods, respectively											Foreign currency translation, net of tax of $(1,464), $6,957, $(1,060), and $1,671 for the three and nine months periods, respectively	(15,312)		20,632		(33,307)		20,087
Pension and other postretirement benefit plans adjustment, net of tax of $(522), $(303), $(1,425), and $(1,229) for the three and nine months periods, respectively											Pension and other postretirement benefit plans adjustment, net of tax of $(522), $(303), $(1,425), and $(1,229) for the three and nine months periods, respectively	1,668		1,037		4,577		4,071
Derivatives qualifying as hedges, net of tax of $(117), $(184), $(45), and $252 for the three and nine months periods, respectively											Derivatives qualifying as hedges, net of tax of $(117), $(184), $(45), and $252 for the three and nine months periods, respectively	662		1,454		1,086		(3,458)
Other comprehensive (loss) income, net of tax:											Other comprehensive (loss) income, net of tax:	(12,982)		23,123		(27,644)		20,700
Comprehensive income	Comprehensive income	$	91,023	$	29,360	$	143,452	$	140,183		Comprehensive income	$	186,199	$	139,710	$	329,651	$	279,893

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


		June 27, 2021		December 31, 2020			September 26, 2021		December 31, 2020
		(Dollars in thousands)					(Dollars in thousands)
ASSETS	ASSETS					ASSETS
Current assets	Current assets					Current assets
Cash and cash equivalents	Cash and cash equivalents	$	361,781	$	375,880	Cash and cash equivalents	$	481,167	$	375,880
Accounts receivable, net	Accounts receivable, net	414,195		395,071		Accounts receivable, net	399,744		395,071
Inventories	Inventories	490,318		513,196		Inventories	484,345		513,196
Prepaid expenses and other current assets	Prepaid expenses and other current assets	116,818		115,436		Prepaid expenses and other current assets	123,776		115,436
Prepaid taxes	Prepaid taxes	27,180		22,842		Prepaid taxes	52,805		22,842
Current assets held-for-sale		26,936		0

Total current assets	Total current assets	1,437,228		1,422,425		Total current assets	1,541,837		1,422,425
Property, plant and equipment, net	Property, plant and equipment, net	449,754		473,912		Property, plant and equipment, net	446,318		473,912
Operating lease assets	Operating lease assets	115,110		100,635		Operating lease assets	129,998		100,635
Goodwill	Goodwill	2,537,432		2,585,966		Goodwill	2,522,950		2,585,966
Intangible assets, net	Intangible assets, net	2,381,329		2,519,746		Intangible assets, net	2,337,249		2,519,746
Deferred tax assets	Deferred tax assets	8,442		8,073		Deferred tax assets	8,425		8,073
Other assets	Other assets	41,666		41,802		Other assets	53,185		41,802
Noncurrent assets held-for-sale		95,426		0

Total assets	Total assets	$	7,066,387	$	7,152,559	Total assets	$	7,039,962	$	7,152,559
LIABILITIES AND EQUITY	LIABILITIES AND EQUITY					LIABILITIES AND EQUITY
Current liabilities	Current liabilities					Current liabilities
Current borrowings	Current borrowings	$	92,500	$	100,500	Current borrowings	$	101,250	$	100,500
Accounts payable	Accounts payable	106,567		102,520		Accounts payable	104,139		102,520
Accrued expenses	Accrued expenses	138,280		136,276		Accrued expenses	127,116		136,276

Payroll and benefit-related liabilities	Payroll and benefit-related liabilities	121,822		122,366		Payroll and benefit-related liabilities	133,523		122,366
Accrued interest	Accrued interest	5,522		7,135		Accrued interest	15,757		7,135
Income taxes payable	Income taxes payable	14,836		17,361		Income taxes payable	17,185		17,361
Other current liabilities	Other current liabilities	46,265		53,869		Other current liabilities	63,240		53,869
Liabilities held-for-sale		1,056		0

Total current liabilities	Total current liabilities	526,848		540,027		Total current liabilities	562,210		540,027
Long-term borrowings	Long-term borrowings	2,215,666		2,377,888		Long-term borrowings	1,948,666		2,377,888
Deferred tax liabilities	Deferred tax liabilities	483,269		484,678		Deferred tax liabilities	479,105		484,678
Pension and postretirement benefit liabilities	Pension and postretirement benefit liabilities	51,179		74,499		Pension and postretirement benefit liabilities	49,843		74,499
Noncurrent liability for uncertain tax positions	Noncurrent liability for uncertain tax positions	10,078		10,127		Noncurrent liability for uncertain tax positions	10,078		10,127

Noncurrent operating lease liabilities	Noncurrent operating lease liabilities	101,302		86,097		Noncurrent operating lease liabilities	114,777		86,097
Other liabilities	Other liabilities	211,943		242,786		Other liabilities	217,411		242,786
Total liabilities	Total liabilities	3,600,285		3,816,102		Total liabilities	3,382,090		3,816,102
Commitments and contingencies	Commitments and contingencies	0		0		Commitments and contingencies	0		0
Total shareholders' equity	Total shareholders' equity	3,466,102		3,336,457		Total shareholders' equity	3,657,872		3,336,457
Total liabilities and shareholders' equity	Total liabilities and shareholders' equity	$	7,066,387	$	7,152,559	Total liabilities and shareholders' equity	$	7,039,962	$	7,152,559

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


		Six Months Ended					Nine Months Ended
		June 27, 2021		June 28, 2020			September 26, 2021		September 27, 2020
		(Dollars in thousands)					(Dollars in thousands)
Cash flows from operating activities of continuing operations:	Cash flows from operating activities of continuing operations:					Cash flows from operating activities of continuing operations:
Net income	Net income	$	158,114	$	142,606	Net income	$	357,295	$	259,193
Adjustments to reconcile net income to net cash provided by operating activities:	Adjustments to reconcile net income to net cash provided by operating activities:					Adjustments to reconcile net income to net cash provided by operating activities:
Income (loss) from discontinued operations		36		(11)
Loss from discontinued operations						Loss from discontinued operations	361		7
Depreciation expense	Depreciation expense	35,982		34,461		Depreciation expense	53,846		51,329
Intangible asset amortization expense	Intangible asset amortization expense	83,867		78,638		Intangible asset amortization expense	124,832		118,649
Deferred financing costs and debt discount amortization expense	Deferred financing costs and debt discount amortization expense	2,388		1,984		Deferred financing costs and debt discount amortization expense	3,438		3,191

Loss on extinguishment of debt	Loss on extinguishment of debt	12,986		0		Loss on extinguishment of debt	12,986		—
Fair value step up of acquired inventory sold	Fair value step up of acquired inventory sold	3,993		1,707		Fair value step up of acquired inventory sold	3,993		1,707
Changes in contingent consideration	Changes in contingent consideration	11,428		(29,951)		Changes in contingent consideration	12,728		(54,585)
Impairment of long-lived assets	Impairment of long-lived assets	6,739		0		Impairment of long-lived assets	6,739		—
Stock-based compensation	Stock-based compensation	11,693		8,482		Stock-based compensation	17,065		14,759
Gain on sale of business						Gain on sale of business	(91,157)		—
Deferred income taxes, net	Deferred income taxes, net	1,050		1,055		Deferred income taxes, net	(67)		2,600
Payments for contingent consideration	Payments for contingent consideration	0		(79,771)		Payments for contingent consideration	(170)		(79,771)
Interest benefit on swaps designated as net investment hedges	Interest benefit on swaps designated as net investment hedges	(9,126)		(9,805)		Interest benefit on swaps designated as net investment hedges	(13,882)		(14,488)
Other	Other	(16,679)		(18,981)		Other	(26,113)		(15,703)
Changes in assets and liabilities, net of effects of acquisitions and disposals:	Changes in assets and liabilities, net of effects of acquisitions and disposals:					Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	Accounts receivable	(23,159)		45,843		Accounts receivable	(13,829)		35,546
Inventories	Inventories	(13,648)		(34,875)		Inventories	(10,951)		(38,096)
Prepaid expenses and other assets	Prepaid expenses and other assets	(16,551)		11,819		Prepaid expenses and other assets	(31,223)		9,393
Accounts payable, accrued expenses and other liabilities	Accounts payable, accrued expenses and other liabilities	32,625		(26,449)		Accounts payable, accrued expenses and other liabilities	84,179		(4,243)
Income taxes receivable and payable, net	Income taxes receivable and payable, net	(16,663)		7,257		Income taxes receivable and payable, net	(39,610)		(48,000)
Net cash provided by operating activities from continuing operations	Net cash provided by operating activities from continuing operations	265,075		134,009		Net cash provided by operating activities from continuing operations	450,460		241,488
Cash flows from investing activities of continuing operations:	Cash flows from investing activities of continuing operations:					Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	Expenditures for property, plant and equipment	(36,659)		(39,052)		Expenditures for property, plant and equipment	(52,090)		(62,369)
Proceeds from sale of assets		404		400
Proceeds from sale of business and assets						Proceeds from sale of business and assets	225,900		400
Payments for businesses and intangibles acquired, net of cash acquired	Payments for businesses and intangibles acquired, net of cash acquired	(3,539)		(265,895)		Payments for businesses and intangibles acquired, net of cash acquired	(4,254)		(266,843)
Deposits		(1,250)		0

Net interest proceeds on swaps designated as net investment hedges	Net interest proceeds on swaps designated as net investment hedges	9,288		9,986		Net interest proceeds on swaps designated as net investment hedges	9,288		9,986
Net cash used in investing activities from continuing operations		(31,756)		(294,561)
Proceeds from sales of investments						Proceeds from sales of investments	7,300		—
Purchase of investments						Purchase of investments	(18,418)		—
Net cash provided by (used in) investing activities from continuing operations						Net cash provided by (used in) investing activities from continuing operations	167,726		(318,826)
Cash flows from financing activities of continuing operations:	Cash flows from financing activities of continuing operations:					Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	Proceeds from new borrowings	400,000		1,010,000		Proceeds from new borrowings	400,000		1,013,807
Reduction in borrowings	Reduction in borrowings	(575,000)		(500,000)		Reduction in borrowings	(834,000)		(788,807)
Debt extinguishment, issuance and amendment fees	Debt extinguishment, issuance and amendment fees	(9,774)		(7,727)		Debt extinguishment, issuance and amendment fees	(9,774)		(8,440)
Net proceeds from share based compensation plans and the related tax impacts	Net proceeds from share based compensation plans and the related tax impacts	6,339		2,668		Net proceeds from share based compensation plans and the related tax impacts	11,366		11,177
Payments for contingent consideration	Payments for contingent consideration	(30,489)		(60,947)		Payments for contingent consideration	(31,388)		(64,135)
Dividends paid	Dividends paid	(31,793)		(31,558)		Dividends paid	(47,716)		(47,384)
Proceeds from sale of treasury stock						Proceeds from sale of treasury stock	11,097		—
Net cash (used in) provided by financing activities from continuing operations	Net cash (used in) provided by financing activities from continuing operations	(240,717)		412,436		Net cash (used in) provided by financing activities from continuing operations	(500,415)		116,218
Cash flows from discontinued operations:	Cash flows from discontinued operations:					Cash flows from discontinued operations:
Net cash used in operating activities	Net cash used in operating activities	(371)		(317)		Net cash used in operating activities	(519)		(540)
Net cash used in discontinued operations	Net cash used in discontinued operations	(371)		(317)		Net cash used in discontinued operations	(519)		(540)
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(6,330)		885		Effect of exchange rate changes on cash and cash equivalents	(11,965)		8,057
Net (decrease) increase in cash and cash equivalents		(14,099)		252,452
Net increase in cash and cash equivalents						Net increase in cash and cash equivalents	105,287		46,397
Cash and cash equivalents at the beginning of the period	Cash and cash equivalents at the beginning of the period	375,880		301,083		Cash and cash equivalents at the beginning of the period	375,880		301,083
Cash and cash equivalents at the end of the period	Cash and cash equivalents at the end of the period	$	361,781	$	553,535	Cash and cash equivalents at the end of the period	$	481,167	$	347,480

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)


		Common Stock			Additional Paid In Capital				Retained Earnings			Accumulated Other Comprehensive Loss		Treasury Stock					Total				Common Stock						Additional Paid In Capital				Retained Earnings				Accumulated Other Comprehensive Loss				Treasury Stock							Total
		Shares	Dollars								Shares			Dollars				Shares				Dollars										Shares								Dollars
		(Dollars and shares in thousands, except per share)																					(Dollars and shares in thousands, except per share)
Balance at December 31, 2020	Balance at December 31, 2020	47,812	$	47,812			$	652,305				$	3,096,228	$	(297,298)	1,132					$	(162,590)		$	3,336,457	Balance at December 31, 2020		47,812			$	47,812			$	652,305			$	3,096,228			$	(297,298)			1,132			$	(162,590)	$	3,336,457

Net income	Net income								74,866										74,866			Net income											74,866															74,866
Cash dividends ($0.34 per share)	Cash dividends ($0.34 per share)								(15,893)										(15,893)			Cash dividends ($0.34 per share)											(15,893)															(15,893)
Other comprehensive loss	Other comprehensive loss											(22,437)							(22,437)			Other comprehensive loss															(22,437)											(22,437)
Shares issued under compensation plans	Shares issued under compensation plans	18	18		1,993									(28)		99			2,110			Shares issued under compensation plans	18			18				1,993												(28)				99			2,110
Deferred compensation	Deferred compensation				447									(4)		241			688			Deferred compensation							447												(4)				241			688
Balance at March 28, 2021	Balance at March 28, 2021	47,830	47,830		654,745				3,155,201			(319,735)		1,100		(162,250)			3,375,791			Balance at March 28, 2021	47,830			47,830			654,745				3,155,201				(319,735)				1,100				(162,250)			3,375,791
Net income	Net income								83,248										83,248			Net income											83,248															83,248
Cash dividends ($0.34 per share)	Cash dividends ($0.34 per share)								(15,900)										(15,900)			Cash dividends ($0.34 per share)											(15,900)															(15,900)
Other comprehensive income	Other comprehensive income											7,775							7,775			Other comprehensive income															7,775											7,775
Shares issued under compensation plans	Shares issued under compensation plans	52	52		15,132									(1)		16			15,200			Shares issued under compensation plans	52			52			15,132												(1)				16			15,200
Deferred compensation	Deferred compensation				0									0		(12)			(12)			Deferred compensation							—												—				(12)			(12)
Balance at June 27, 2021	Balance at June 27, 2021	47,882	$	47,882	$	669,877			$	3,222,549		$	(311,960)	1,099		$	(162,246)		$	3,466,102		Balance at June 27, 2021	47,882			$	47,882		$	669,877			$	3,222,549			$	(311,960)			1,099				$	(162,246)		$	3,466,102
Net income																						Net income											199,181															199,181
Cash dividends ($0.34 per share)																						Cash dividends ($0.34 per share)											(15,923)															(15,923)
Other comprehensive loss																						Other comprehensive loss															(12,982)											(12,982)
Shares issued under compensation plans																						Shares issued under compensation plans	33			33			10,374												—				(10)			10,397
Treasury stock reissued																						Treasury stock reissued							6,349												(28)				4,748			11,097
Balance at September 26, 2021																						Balance at September 26, 2021	47,915			$	47,915		$	686,600			$	3,405,807			$	(324,942)			1,071				$	(157,508)		$	3,657,872


		Common Stock			Additional Paid In Capital				Retained Earnings			Accumulated Other Comprehensive Loss		Treasury Stock					Total				Common Stock						Additional Paid In Capital				Retained Earnings				Accumulated Other Comprehensive Loss				Treasury Stock							Total
		Shares	Dollars								Shares			Dollars				Shares				Dollars										Shares								Dollars
		(Dollars and shares in thousands, except per share)																					(Dollars and shares in thousands, except per share)
Balance at December 31, 2019	Balance at December 31, 2019	47,536	$	47,536			$	616,980				$	2,824,916	$	(344,392)	1,182					$	(165,720)		$	2,979,320	Balance at December 31, 2019		47,536			$	47,536			$	616,980			$	2,824,916			$	(344,392)			1,182			$	(165,720)	$	2,979,320
Cumulative effect adjustment resulting from the adoption of new accounting standards	Cumulative effect adjustment resulting from the adoption of new accounting standards								(791)										(791)			Cumulative effect adjustment resulting from the adoption of new accounting standards											(791)															(791)
Net income	Net income								131,150										131,150			Net income											131,150															131,150
Cash dividends ($0.34 per share)	Cash dividends ($0.34 per share)								(15,767)										(15,767)			Cash dividends ($0.34 per share)											(15,767)															(15,767)
Other comprehensive loss	Other comprehensive loss											(20,327)							(20,327)			Other comprehensive loss															(20,327)											(20,327)
Shares issued under compensation plans	Shares issued under compensation plans	24	24		(3,074)									(37)		1,748			(1,302)			Shares issued under compensation plans	24			24				(3,074)												(37)				1,748			(1,302)
Deferred compensation	Deferred compensation				383									(5)		358			741			Deferred compensation							383												(5)				358			741
Balance at March 29, 2020	Balance at March 29, 2020	47,560	47,560		614,289				2,939,508			(364,719)		1,140		(163,614)			3,073,024			Balance at March 29, 2020	47,560			47,560			614,289				2,939,508				(364,719)				1,140				(163,614)			3,073,024
Net income	Net income								11,456										11,456			Net income											11,456															11,456
Cash dividends ($0.34 per share)	Cash dividends ($0.34 per share)								(15,791)										(15,791)			Cash dividends ($0.34 per share)											(15,791)															(15,791)
Other comprehensive income	Other comprehensive income											17,904							17,904			Other comprehensive income															17,904											17,904
Shares issued under compensation plans	Shares issued under compensation plans	35	35		10,516									(3)		175			10,726			Shares issued under compensation plans	35			35			10,516												(3)				175			10,726
Deferred compensation	Deferred compensation				0									(1)		83			83			Deferred compensation							—												(1)				83			83
Balance as of June 28, 2020	Balance as of June 28, 2020	47,595	$	47,595	$	624,805			$	2,935,173		$	(346,815)	1,136		$	(163,356)		$	3,097,402		Balance as of June 28, 2020	47,595			47,595			624,805				2,935,173				(346,815)				1,136				(163,356)			3,097,402

Net income																						Net income											116,587															116,587
Cash dividends ($0.34 per share)																						Cash dividends ($0.34 per share)											(15,826)															(15,826)
Other comprehensive income																						Other comprehensive income															23,123											23,123
Shares issued under compensation plans																						Shares issued under compensation plans	102			102			14,671												(1)				13			14,786
Deferred compensation																						Deferred compensation							(228)												—				359			131
Balance at September 27, 2020																						Balance at September 27, 2020	47,697			$	47,697		$	639,248			$	3,035,934			$	(323,692)			1,135				$	(162,984)		$	3,236,203

The accompanying notes are an integral part of the condensed consolidated financial statements.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(all tabular amounts in thousands unless otherwise noted)

Note 1 — Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements.

In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Note 2 — Recently issued accounting standards

In December 2019, the FASB issued new guidance that simplifies various aspects of accounting for income taxes including those related to the step-up in the tax basis of goodwill, intraperiod tax allocations and the interim period effects of changes in tax laws or rates. The new guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The modifications under the new guidance were applied on a prospective basis effective January 1, 2021. The adoption of the new guidance did not have a material effect on the condensed consolidated financial statements.

From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.

Note 3 — Net revenues

We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For our Original Equipment and Development Services ("OEM") segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which ~~comprised~~constituted 89%, 9% and 2% of consolidated net revenues, respectively, for the ~~six~~nine months ended ~~June 27,~~September 26, 2021. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table disaggregates revenue by global product category for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020.


		Three Months Ended				Six Months Ended					Three Months Ended				Nine Months Ended
		June 27, 2021		June 28, 2020		June 27, 2021		June 28, 2020			September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Vascular access	Vascular access	$	167,739	$	164,958	$	331,712	$	315,214	Vascular access	$	175,476	$	160,052	$	507,188	$	475,252
Anesthesia	Anesthesia	95,426		64,867		180,283		140,569		Anesthesia	97,074		75,647		277,357		216,204
Interventional	Interventional	112,082		82,594		208,255		182,525		Interventional	104,304		93,187		312,559		275,704
Surgical	Surgical	98,185		67,275		178,571		142,707		Surgical	92,831		82,223		271,402		224,928
Interventional urology	Interventional urology	92,243		40,094		165,607		114,286		Interventional urology	83,107		81,773		248,714		196,114
OEM	OEM	60,956		55,832		114,445		119,219		OEM	64,083		49,399		178,528		168,618
Other (1)	Other (1)	86,842		91,414		168,525		183,156		Other (1)	83,376		86,020		251,901		269,157
Net revenues (2)	Net revenues (2)	$	713,473	$	567,034	$	1,347,398	$	1,197,676	Net revenues (2)	$	700,251	$	628,301	$	2,047,649	$	1,825,977

(1)Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products).

(2)The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments include net revenues from each of the non-OEM product categories listed above.

Note 4 — Acquisitions and divestitures

Acquisitions

On February 18, 2020, we acquired IWG High Performance Conductors, Inc. ("HPC"), a privately-held original equipment manufacturer of minimally invasive medical products and high performance conductors. The acquisition complements our OEM product portfolio.

On December 28, 2020, we acquired Z-Medica, LLC ("Z-Medica"), a privately-held medical device company that manufactures and sells hemostatic (hemorrhage control) products, marketed under the QuikClot, Combat Gauze and QuickClot Control+ brand names, to complement our anesthesia product portfolio. The acquisition included an initial cash purchase price of $500.0 million, with the potential to make an additional payment up to $25 million upon the achievement of certain commercial milestones.

Divestiture

On May 15, 2021, we entered into a definitive agreement to sell certain product lines within our global respiratory product portfolio (the "Divested respiratory business") to Medline Industries, Inc. (“Medline”) for consideration of $286.0 million, reduced by $12 million in working capital not transferring to Medline, ~~and~~which is subject to customary ~~post-close~~post close adjustments (the "Respiratory business divestiture"). In connection with the Respiratory business divestiture, we also entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services, including a manufacturing and supply transition agreement (the "MSTA").

On June 28, 2021, the first day of the third quarter of 2021, we completed the initial phase of the Respiratory business divestiture, pursuant to which we received cash proceeds of $259 million. We attributed $33.8 million of the proceeds to our performance obligations pursuant to the MSTA. The resulting liability was measured as the excess of the estimated fair value of the services to be performed over the estimated proceeds we expect to receive over the MSTA term. It was recorded within Other current liabilities and ~~we estimate that we~~Other liabilities in the condensed consolidated balance sheet and the related proceeds will ~~recognize a pre-tax gain on~~be recognized in net revenues as the ~~sale of approximately $100 million.~~ services are performed.

The second phase of the Respiratory business divestiture will occur once we transfer certain additional manufacturing assets to Medline. Our receipt of $15.0 million in additional cash proceeds is contingent upon the transfer of these manufacturing assets and is expected to occur prior to the end of 2023. We plan to recognize the contingent consideration, and any gain on sale resulting from the second phase of the divestiture, when it becomes realizable. In connection with the Respiratory business divestiture, we entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services.

Net sales attributable to our Divested respiratory business are included within each of our geographic segments and were $29.6 million and $60.7 million during the three and six months ended June 27, 2021, respectively, and $138.5 million during the year ended December 31, 2020. As a result of the Respiratory business divestiture, the following assets and liabilities were designated as assets and liabilities held for sale as of June 27, 2021:

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following assets and liabilities were sold as part of the initial phase of the Respiratory business divestiture:


	~~June 27, 2021~~
Assets
Inventories	$	~~26,936~~26,830
Current assets ~~held-for-sale~~	~~26,936~~26,830

Property, plant and equipment, net	17,006
Intangible assets, net	41,583
Goodwill	35,745
Operating lease assets	1,053
Other assets	3994
Noncurrent assets ~~held-for-sale~~	~~95,426~~95,481

Total assets ~~held-for-sale~~	$	~~122,362~~122,311
Liabilities
Other current liabilities	$	~~488~~535
Noncurrent operating lease liabilities	568
Liabilities ~~held-for-sale~~	$	~~1,056~~1,103

Net revenues attributable to our Divested respiratory business recognized prior to the Respiratory business divestiture are included within each of our geographic segments and were $60.7 million during the nine months ended September 26, 2021, and $29.8 million and $102.5 million for the three and nine months ended September 27, 2020, respectively. For the three and nine months ended September 27, 2021, we recognized $27.9 million in net revenues attributed to services provided to Medline in accordance with the MSTA, which are presented within our Americas reporting segment.

Note 5 — Restructuring and impairment charges

Respiratory divestiture plan

During the second quarter of 2021, in connection with the Respiratory business divestiture described in Note 4, we committed to a restructuring plan designed to separate the manufacturing operations ~~that will~~to be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites ~~that will be~~being transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan:


			Total estimated amount expected to be incurred
Program expense estimates:			(Dollars in millions)
Restructuring charges (1)			$5 million to $8 million
Restructuring related charges (2)			$19 million to $22 million
Total restructuring and restructuring related charges			$24 million to $30 million

(1)Substantially all of the charges consist of employee termination benefit costs.

(2)Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays, the majority of which will be made in 2022 and 2023. Additionally, we expect to incur $22 million to $28 million in aggregate capital expenditures under the plan, which are expected to be incurred mostly in 2022 and 2023. As of ~~June 27,~~September 26, 2021, we had a restructuring reserve of ~~$2.5~~$2.6 million related to this plan, all of which related to termination benefits.

2021 Restructuring plan

During the first quarter of 2021, we committed to a restructuring plan designed to streamline various business functions across our segments. We estimate that we will incur aggregate pre-tax restructuring charges of $7 million to $9 million, consisting primarily of termination benefits. In addition, we expect to incur $3 million to $4 million in

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

restructuring related charges, most of which are expected to be recognized in cost of goods sold. We expect this plan will be substantially completed by the end of 2021. As of ~~June 27,~~September 26, 2021, we had a restructuring reserve of ~~$5.1~~$4.1 million related to this plan, all of which related to termination benefits.

Footprint realignment plans

We have ongoing restructuring programs related to the relocation of manufacturing operations to existing lower-cost locations and related workforce reductions (referred to as the 2019, 2018 and 2014 Footprint realignment plans). The following tables provide a summary of our cost estimates and other information associated with these ongoing Footprint realignment plans:

2019 Footprint realignment plan

2018 Footprint realignment plan

2014 Footprint realignment plan

2019 Footprint realignment plan

2018 Footprint realignment plan

2014 Footprint realignment plan

Program expense estimates:

(Dollars in millions)

Program expense estimates:

(Dollars in millions)

Termination benefits

$14 to $16

$60 to $70

$13 to $13

Termination benefits

$14 to $16

$60 to $70

$13 to $13

Other costs (1)

2 to 2

3 to 4

1 to 2

Other costs (1)

2 to 2

3 to 4

1 to 2

Restructuring charges

16 to 18

63 to 74

14 to 15

Restructuring charges

16 to 18

63 to 74

14 to 15

Restructuring related charges (2)

38 to 43

40 to 59

38 to 40

Restructuring related charges (2)

38 to 43

40 to 59

38 to 40

Total restructuring and restructuring related charges

$54 to $61

$103 to $133

$52 to $55

Total restructuring and restructuring related charges

$54 to $61

$103 to $133

$52 to $55

Other program estimates:

Expected cash outlays

$48 to $55

$99 to $127

$42 to $46

Expected cash outlays

$48 to $55

$99 to $127

$42 to $46

Expected capital expenditures

$28 to $33

$19 to $23

$26 to $27

Expected capital expenditures

$28 to $33

$16 to $17

$26 to $27

Other program information:

Period initiated

February 2019

May 2018

April 2014

Period initiated

February 2019

May 2018

April 2014

Estimated period of substantial completion

2022

Estimated period of substantial completion

2022

Aggregate restructuring charges

$15.5

$61.9

$13.7

Aggregate restructuring charges

$15.6

$62.1

$13.8

Restructuring reserve:

Balance as of June 27, 2021

$5.4

$47.2

$3.1

Balance as of September 26, 2021

$4.0

$45.7

$3.0

Restructuring related charges incurred:

Three Months Ended June 27, 2021

$3.9

$2.3

$1.0

Six Months Ended June 27, 2021

$7.4

$4.3

$1.7

Three Months Ended September 26, 2021

$3.2

$2.2

$0.4

Nine Months Ended September 26, 2021

$10.7

$6.5

$2.1

Aggregate restructuring related charges

$28.6

$21.0

$37.7

Aggregate restructuring related charges

$31.8

$23.2

$38.1

(1)Includes facility closure, employee relocation, equipment relocation and outplacement costs.

(2)Restructuring related charges represent costs that are directly related to the programs and principally constitute costs to transfer manufacturing operations to the existing lower-cost locations, project management costs and accelerated depreciation. The 2018 Footprint realignment plan also includes a charge associated with our exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the restructuring related charges are expected to be recognized within cost of goods sold.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Restructuring and impairment charges recognized for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020 consisted of the following:

Three Months Ended June 27, 2021
Termination benefits
Other costs (1)
Total
Respiratory divestiture plan $ 2,540 $ 1 $ 2,541
2021 Restructuring plan 129 23 152
2019 Footprint realignment plan (301) 91 (210)
2018 Footprint realignment plan 1,459 92 1,551
Other restructuring programs (2)
(4) 725 721
Restructuring charges 3,823 932 4,755
Asset impairment charges 0 6,739 6,739
Restructuring and impairment charges $ 3,823 $ 7,671 $ 11,494
Three Months Ended June 28, 2020
Termination benefits
Other costs (1)
Total
2020 Workforce reduction plan $ 10,564 $ 0 $ 10,564
2019 Footprint realignment plan 323 82 405
2018 Footprint realignment plan 7,545 52 7,597
Other restructuring programs (2)
169 270 439
Restructuring charges $ 18,601 $ 404 $ 19,005


Three Months Ended September 26, 2021
	Termination benefits		Other costs (1)		Total
Respiratory divestiture plan	$	126	$	(1)	$	125
2021 Restructuring plan	226		42		268
2019 Footprint realignment plan	9		86		95
2018 Footprint realignment plan	191		10		201
Other restructuring programs (2)	60		210		270
Restructuring charges	$	612	$	347	$	959


Three Months Ended September 27, 2020
	Termination benefits		Other costs (1)		Total
2020 Workforce reduction plan	$	(471)	$	255	$	(216)
2019 Footprint realignment plan	(785)		368		(417)
2018 Footprint realignment plan	(3,006)		83		(2,923)
Other restructuring programs	(151)		48		(103)
Restructuring charges	$	(4,413)	$	754	$	(3,659)


Six Months Ended June 27, 2021
Nine Months Ended September 26, 2021								Nine Months Ended September 26, 2021
		Termination benefits		Other costs (1)		Total			Termination benefits		Other costs (1)		Total
Respiratory divestiture plan	Respiratory divestiture plan	$	2,540	$	1	$	2,541	Respiratory divestiture plan	$	2,666	$	—	$	2,666
2021 Restructuring plan	2021 Restructuring plan	6,889		23		6,912		2021 Restructuring plan	7,115		65		7,180

2019 Footprint realignment plan	2019 Footprint realignment plan	40		196		236		2019 Footprint realignment plan	49		282		331
2018 Footprint realignment plan	2018 Footprint realignment plan	1,726		137		1,863		2018 Footprint realignment plan	1,917		147		2,064
Other restructuring programs (2)	Other restructuring programs (2)	(170)		1,371		1,201		Other restructuring programs (2)	(110)		1,581		1,471
Restructuring charges	Restructuring charges	11,025		1,728		12,753		Restructuring charges	11,637		2,075		13,712
Asset impairment charges	Asset impairment charges	0		6,739		6,739		Asset impairment charges	—		6,739		6,739
Restructuring and impairment charges	Restructuring and impairment charges	$	11,025	$	8,467	$	19,492	Restructuring and impairment charges	$	11,637	$	8,814	$	20,451


Six Months Ended June 28, 2020
Nine Months Ended September 27, 2020								Nine Months Ended September 27, 2020
		Termination benefits		Other costs (1)		Total			Termination benefits		Other costs (1)		Total
2020 Workforce reduction plan	2020 Workforce reduction plan	$	10,564	$	0	$	10,564	2020 Workforce reduction plan	$	10,093	$	255	$	10,348
2019 Footprint realignment plan	2019 Footprint realignment plan	1,152		91		1,243		2019 Footprint realignment plan	367		459		826
2018 Footprint realignment plan	2018 Footprint realignment plan	7,859		133		7,992		2018 Footprint realignment plan	4,853		216		5,069
Other restructuring programs ~~(2)~~	Other restructuring programs ~~(2)~~	62		490		552		Other restructuring programs ~~(2)~~	(89)		538		449
Restructuring charges	Restructuring charges	$	19,637	$	714	$	20,351	Restructuring charges	$	15,224	$	1,468	$	16,692

(1) Other costs include facility closure, contract termination and other exit costs.

(2) Includes the 2020 Workforce reduction plan, the program initiated during third quarter of 2019 ~~as well as~~and the ~~2016 and~~ 2014 Footprint realignment ~~plans.~~plan.

Impairment Charges

~~For~~During the ~~three and six months ended June 27,~~second quarter of 2021, we recorded impairment charges of $6.7 million related to our decision to abandon intellectual property and other assets primarily associated with our respiratory product portfolio that was not transferred to Medline as part of the Respiratory business divestiture described in Note 4.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 6 — Inventories

Inventories as of ~~June 27,~~September 26, 2021 and December 31, 2020 consisted of the following:
June 27, 2021 December 31, 2020
Raw materials $ 133,722 $ 132,370
Work-in-process 78,088 75,874
Finished goods 278,508 304,952
Inventories $ 490,318 $ 513,196


	September 26, 2021		December 31, 2020
Raw materials	$	135,293	$	132,370
Work-in-process	81,177		75,874
Finished goods	267,875		304,952
Inventories	$	484,345	$	513,196

Note 7 — Goodwill and other intangible assets

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the ~~six~~nine months ended ~~June 27,~~September 26, 2021:


		Americas		EMEA		Asia		OEM		Total			Americas		EMEA		Asia		OEM		Total
December 31, 2020	December 31, 2020	$	1,700,282	$	536,228	$	237,446	$	112,010	$	2,585,966	December 31, 2020	$	1,700,282	$	536,228	$	237,446	$	112,010	$	2,585,966

Goodwill held-for-sale		(21,802)		(7,537)		(6,406)		0		(35,745)

Goodwill disposed												Goodwill disposed	(21,802)		(7,537)		(6,406)		—		(35,745)
Goodwill related to acquisitions												Goodwill related to acquisitions	(2,716)		(405)		(284)		—		(3,405)
Currency translation adjustment	Currency translation adjustment	1,081		(9,507)		(4,363)		0		(12,789)		Currency translation adjustment	1,044		(19,197)		(5,713)		—		(23,866)
June 27, 2021		$	1,679,561	$	519,184	$	226,677	$	112,010	$	2,537,432
September 26, 2021												September 26, 2021	$	1,676,808	$	509,089	$	225,043	$	112,010	$	2,522,950

The gross carrying amount of, and accumulated amortization relating to, intangible assets as of ~~June 27,~~September 26, 2021 and December 31, 2020 were as follows:


		Gross Carrying Amount				Accumulated Amortization					Gross Carrying Amount				Accumulated Amortization
		June 27, 2021		December 31, 2020		June 27, 2021		December 31, 2020			September 26, 2021		December 31, 2020		September 26, 2021		December 31, 2020
Customer relationships	Customer relationships	$	1,335,685	$	1,377,943	$	(414,086)	$	(425,692)	Customer relationships	$	1,333,471	$	1,377,943	$	(428,072)	$	(425,692)
In-process research and development	In-process research and development	29,136		29,627		—		—		In-process research and development	28,797		29,627		—		—
Intellectual property	Intellectual property	1,444,105		1,458,924		(519,239)		(479,612)		Intellectual property	1,442,851		1,458,924		(540,472)		(479,612)
Distribution rights	Distribution rights	23,722		23,866		(20,525)		(20,280)		Distribution rights	23,622		23,866		(20,621)		(20,280)
Trade names	Trade names	555,192		619,847		(53,519)		(65,955)		Trade names	553,387		619,847		(56,462)		(65,955)
Non-compete agreements	Non-compete agreements	24,002		24,592		(23,144)		(23,514)		Non-compete agreements	23,571		24,592		(22,823)		(23,514)
		$	3,411,842	$	3,534,799	$	(1,030,513)	$	(1,015,053)		$	3,405,699	$	3,534,799	$	(1,068,450)	$	(1,015,053)

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 8 — Borrowings

Our borrowings at ~~June 27,~~September 26, 2021 and December 31, 2020 were as follows:


		June 27, 2021		December 31, 2020			September 26, 2021		December 31, 2020
Senior Credit Facility:	Senior Credit Facility:					Senior Credit Facility:
Revolving credit facility, at a rate of 1.59% at June 27, 2021, due 2024		$	600,500	$	350,000
Term loan facility, at a rate of 1.59% at June 27, 2021, due 2024		647,500		673,000
Revolving credit facility, at a rate of 1.46% at September 26, 2021, due 2024						Revolving credit facility, at a rate of 1.46% at September 26, 2021, due 2024	$	341,500	$	350,000
Term loan facility, at a rate of 1.46% at September 26, 2021, due 2024						Term loan facility, at a rate of 1.46% at September 26, 2021, due 2024	647,500		673,000

4.875% Senior Notes due 2026	4.875% Senior Notes due 2026	0		400,000		4.875% Senior Notes due 2026	—		400,000
4.625% Senior Notes due 2027	4.625% Senior Notes due 2027	500,000		500,000		4.625% Senior Notes due 2027	500,000		500,000
4.25% Senior Notes due 2028	4.25% Senior Notes due 2028	500,000		500,000		4.25% Senior Notes due 2028	500,000		500,000
Securitization program, at a rate of 1.20% at June 27, 2021		75,000		75,000
Securitization program, at a rate of 0.84% at September 26, 2021						Securitization program, at a rate of 0.84% at September 26, 2021	75,000		75,000
		2,323,000		2,498,000			2,064,000		2,498,000
Less: Unamortized debt issuance costs	Less: Unamortized debt issuance costs	(14,834)		(19,612)		Less: Unamortized debt issuance costs	(14,084)		(19,612)
		2,308,166		2,478,388			2,049,916		2,478,388
Current borrowings	Current borrowings	(92,500)		(100,500)		Current borrowings	(101,250)		(100,500)

Long-term borrowings	Long-term borrowings	$	2,215,666	$	2,377,888	Long-term borrowings	$	1,948,666	$	2,377,888

Redemption of 4.875% Senior Notes due 2026

On April 29, 2021, we issued a notice of redemption to holders of our outstanding $400 million aggregate principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”). Pursuant to the notice of redemption, the 2026 Notes were redeemed on June 1, 2021 (the “Redemption Date”) using borrowings under the revolving credit facility and cash on hand at a redemption price equal to 102.438% of the principal amount of the 2026 Notes plus accrued and unpaid interest up to, but not including, the Redemption Date (the “Redemption Price”). We recognized a loss on extinguishment of debt of $13.0 million as a result of the redemption of the 2026 Notes.

~~Subsequent event~~Repayment of revolving credit facility due 2024

~~On July 6,~~During the third quarter of 2021, we repaid $259 million in borrowings under our revolving credit facility using funds primarily consisting of proceeds we received from the initial close of the Respiratory business divestiture described in Note 4.

Note 9 — Financial instruments

Foreign currency forward contracts

We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with our currency translation exposures, which generally approximate one month. For the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 we recognized ~~a gain~~losses of ~~$0.7~~$2.7 million and ~~a loss of $2.5~~$5.2 million, respectively, related to non-designated foreign currency forward contracts. For the three and ~~six~~nine months ended ~~June 28,~~September 27, 2020 we recognized ~~a loss~~losses of ~~$0.8~~$0.9 million and ~~a gain of $0.8~~$0.1 million, respectively, related to non-designated foreign currency forward contracts.

The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of ~~June 27,~~September 26, 2021 and December 31, 2020 was ~~$137.0~~$148.4 million and $129.5 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of ~~June 27,~~September 26, 2021 and December 31, 2020 was ~~$189.2~~$174.4 million and $163.5 million, respectively. All open foreign currency forward contracts as of ~~June 27,~~September 26, 2021 have durations of 12 months or less.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Cross-currency interest rate swaps

During 2019, we entered into cross-currency swap agreements with 5 different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $250 million at an annual interest rate of 4.875% for €219.2 million at an annual interest rate of 2.4595%. The swap agreements are designed as net investment hedges and expire on March 4, 2024.

During 2018, we entered into cross-currency swap agreements with 6 different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements are designed as net investment hedges and expire on October 4, 2023.

The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement.

The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI"). The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020:


		Three Months Ended				Six Months Ended					Three Months Ended				Nine Months Ended
		June 27, 2021		June 28, 2020		June 27, 2021		June 28, 2020			September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Foreign exchange (losses) gains		$	(7,127)	$	(7,408)	$	10,487	$	17,607
Foreign exchange gains (losses)										Foreign exchange gains (losses)	$	8,873	$	(23,172)	$	19,360	$	(5,565)
Interest benefit	Interest benefit	4,479		4,931		9,126		9,805		Interest benefit	4,756		4,684		13,882		14,488

Balance sheet presentation

The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of ~~June 27,~~September 26, 2021 and December 31, 2020:


		June 27, 2021		December 31, 2020			September 26, 2021		December 31, 2020

Asset derivatives:	Asset derivatives:					Asset derivatives:
Designated foreign currency forward contracts	Designated foreign currency forward contracts	$	1,199	$	1,691	Designated foreign currency forward contracts	$	1,151	$	1,691
Non-designated foreign currency forward contracts	Non-designated foreign currency forward contracts	73		61		Non-designated foreign currency forward contracts	60		61
Cross-currency interest rate swaps	Cross-currency interest rate swaps	20,633		20,106		Cross-currency interest rate swaps	25,684		20,106
Prepaid expenses and other current assets	Prepaid expenses and other current assets	21,905		21,858		Prepaid expenses and other current assets	26,895		21,858

Total asset derivatives	Total asset derivatives	$	21,905	$	21,858	Total asset derivatives	$	26,895	$	21,858
Liability derivatives:	Liability derivatives:					Liability derivatives:
Designated foreign currency forward contracts	Designated foreign currency forward contracts	$	1,372	$	1,504	Designated foreign currency forward contracts	$	687	$	1,504
Non-designated foreign currency forward contracts	Non-designated foreign currency forward contracts	430		366		Non-designated foreign currency forward contracts	286		366
Other current liabilities	Other current liabilities	1,802		1,870		Other current liabilities	973		1,870
Cross-currency interest rate swaps	Cross-currency interest rate swaps	21,183		34,125		Cross-currency interest rate swaps	9,946		34,125
Other liabilities	Other liabilities	21,183		34,125		Other liabilities	9,946		34,125
Total liability derivatives	Total liability derivatives	$	22,985	$	35,995	Total liability derivatives	$	10,919	$	35,995

See Note 11 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax.

~~There was 0 ineffectiveness related to our cash flow hedges during the three and six months ended June 27, 2021 and June 28, 2020.~~

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

There was no ineffectiveness related to our cash flow hedges during the three and nine months ended September 26, 2021 and September 27, 2020.

Trade receivables

The allowance for credit losses as of ~~June 27,~~September 26, 2021 and December 31, 2020 was ~~$12.1~~$11.5 million and $12.9 million, respectively. The current portion of the allowance for credit losses, which was ~~$7.1~~$6.6 million and $8.1 million as of ~~June 27,~~September 26, 2021 and December 31, 2020, respectively, was recognized as a reduction of accounts receivable, net.

Note 10 — Fair value measurement

The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of ~~June 27,~~September 26, 2021 and December 31, 2020:


		Total carrying value at June 27, 2021		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)			Total carrying value at September 26, 2021		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	Investments in marketable securities	$	14,287	$	14,287	$	0	$	0	Investments in marketable securities	$	18,467	$	18,467	$	—	$	—
Derivative assets	Derivative assets	21,905		0		21,905		0		Derivative assets	26,895		—		26,895		—
Derivative liabilities	Derivative liabilities	22,985		0		22,985		0		Derivative liabilities	10,919		—		10,919		—
Contingent consideration liabilities	Contingent consideration liabilities	13,974		0		0		13,974		Contingent consideration liabilities	14,180		—		—		14,180


		Total carrying value at December 31, 2020		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)			Total carrying value at December 31, 2020		Quoted prices in active markets (Level 1)		Significant other observable Inputs (Level 2)		Significant unobservable Inputs (Level 3)
Investments in marketable securities	Investments in marketable securities	$	12,617	$	12,617	$	0	$	0	Investments in marketable securities	$	12,617	$	12,617	$	—	$	—
Derivative assets	Derivative assets	21,858		0		21,858		0		Derivative assets	21,858		—		21,858		—
Derivative liabilities	Derivative liabilities	35,995		0		35,995		0		Derivative liabilities	35,995		—		35,995		—
Contingent consideration liabilities	Contingent consideration liabilities	36,633		0		0		36,633		Contingent consideration liabilities	36,633		—		—		36,633

Valuation Techniques

Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under our benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices.

Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forwards and cross-currency interest rate swaps to manage foreign currency transaction exposure, as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forwards and cross-currency swaps by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties.

Our financial liabilities valued based upon Level 3 inputs (inputs that are not observable in the market) are comprised of contingent consideration arrangements pertaining to our acquisitions, which are discussed immediately below.

Contingent consideration

Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates.

~~The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration.~~

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration.

Contingent Consideration Liability

Valuation Technique

Unobservable Input

Range (Weighted average)

Milestone-based payments

Discounted cash flow

Discount rate

~~1.2%~~1.5% - ~~2.5% (1.9%~~1.8% (1.7%)

Projected year of payment

~~2021~~2022 - 2023

Revenue-based payments

Discounted cash flow

Discount rate

~~1.3%~~1.8% - 10.0% ~~(4.4%~~(4.7%)

Projected year of payment

2021 - 2029

The following table provides information regarding changes in the contingent consideration liabilities during the ~~six~~nine months ended ~~June 27,~~September 26, 2021:


	Contingent consideration

Balance - December 31, 2020	$	36,633
Payments (1)	~~(30,489)~~(31,558)
Revaluations and other adjustments	~~7,848~~9,148
Translation adjustments	~~(18)~~(43)
Balance - ~~June 27,~~September 26, 2021	$	~~13,974~~14,180

(1) Includes $17.4 million payment associated with a settlement reached with the shareholders from whom we acquired Essential Medical, Inc. See Note 13 for additional information related to the settlement.

Note 11 — Shareholders’ equity

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:


		Three Months Ended		Six Months Ended			Three Months Ended		Nine Months Ended
		June 27, 2021	June 28, 2020	June 27, 2021	June 28, 2020		September 26, 2021	September 27, 2020	September 26, 2021	September 27, 2020
Basic	Basic	46,741	46,442	46,719	46,412	Basic	46,810	46,530	46,749	46,451
Dilutive effect of share-based awards	Dilutive effect of share-based awards	692	800	701	825	Dilutive effect of share-based awards	642	803	682	818

Diluted	Diluted	47,433	47,242	47,420	47,237	Diluted	47,452	47,333	47,431	47,269

The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.1 million for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~0.2 million and 0.1 million for the three and six months ended June 28,~~September 27, 2020, respectively.

The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020:


		Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income			Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2020	Balance as of December 31, 2020	$	(482)	$	(150,257)	$	(146,559)	$	(297,298)	Balance as of December 31, 2020	$	(482)	$	(150,257)	$	(146,559)	$	(297,298)
Other comprehensive (loss) income before reclassifications		(574)		9		(17,995)		(18,560)
Other comprehensive income (loss) before reclassifications										Other comprehensive income (loss) before reclassifications	(77)		245		(33,307)		(33,139)
Amounts reclassified from accumulated other comprehensive income	Amounts reclassified from accumulated other comprehensive income	998		2,900		0		3,898		Amounts reclassified from accumulated other comprehensive income	1,163		4,332		—		5,495
Net current-period other comprehensive income (loss)	Net current-period other comprehensive income (loss)	424		2,909		(17,995)		(14,662)		Net current-period other comprehensive income (loss)	1,086		4,577		(33,307)		(27,644)

Balance as of June 27, 2021		$	(58)	$	(147,348)	$	(164,554)	$	(311,960)
Balance as of September 26, 2021										Balance as of September 26, 2021	$	604	$	(145,680)	$	(179,866)	$	(324,942)

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)


		Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income			Cash Flow Hedges		Pension and Other Postretirement Benefit Plans		Foreign Currency Translation Adjustment		Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2019	Balance as of December 31, 2019	$	735	$	(138,810)	$	(206,317)	$	(344,392)	Balance as of December 31, 2019	$	735	$	(138,810)	$	(206,317)	$	(344,392)
Other comprehensive (loss) income before reclassifications	Other comprehensive (loss) income before reclassifications	(4,189)		183		(545)		(4,551)		Other comprehensive (loss) income before reclassifications	(4,479)		(109)		20,087		15,499
Amounts reclassified from accumulated other comprehensive loss	Amounts reclassified from accumulated other comprehensive loss	(723)		2,851		0		2,128		Amounts reclassified from accumulated other comprehensive loss	1,021		4,180		—		5,201
Net current-period other comprehensive (loss) income	Net current-period other comprehensive (loss) income	(4,912)		3,034		(545)		(2,423)		Net current-period other comprehensive (loss) income	(3,458)		4,071		20,087		20,700

Balance as of June 28, 2020		$	(4,177)	$	(135,776)	$	(206,862)	$	(346,815)
Balance as of September 27, 2020										Balance as of September 27, 2020	$	(2,723)	$	(134,739)	$	(186,230)	$	(323,692)

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020:


		Three Months Ended				Six Months Ended					Three Months Ended				Nine Months Ended
		June 27, 2021		June 28, 2020		June 27, 2021		June 28, 2020			September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Losses (gains) on foreign exchange contracts:	Losses (gains) on foreign exchange contracts:									Losses (gains) on foreign exchange contracts:
Cost of goods sold	Cost of goods sold	$	133	$	(685)	$	979	$	(751)	Cost of goods sold	$	164	$	1,899	$	1,143	$	1,148
Total before tax	Total before tax	133		(685)		979		(751)		Total before tax	164		1,899		1,143		1,148
Taxes		27		19		19		28
Taxes (benefit)										Taxes (benefit)	1		(155)		20		(127)
Net of tax	Net of tax	$	160	$	(666)	$	998	$	(723)	Net of tax	$	165	$	1,744	$	1,163	$	1,021
Amortization of pension and other postretirement benefit items (1):	Amortization of pension and other postretirement benefit items (1):									Amortization of pension and other postretirement benefit items (1):
Actuarial losses	Actuarial losses	$	2,144	$	1,850	$	4,287	$	3,702	Actuarial losses	$	2,121	$	1,731	$	6,408	$	5,433
Prior-service costs	Prior-service costs	(251)		8		(502)		16		Prior-service costs	(251)		9		(753)		25

Total before tax	Total before tax	1,893		1,858		3,785		3,718		Total before tax	1,870		1,740		5,655		5,458
Tax benefit	Tax benefit	(443)		(433)		(885)		(867)		Tax benefit	(438)		(411)		(1,323)		(1,278)
Net of tax	Net of tax	$	1,450	$	1,425	$	2,900	$	2,851	Net of tax	$	1,432	$	1,329	$	4,332	$	4,180
Total reclassifications, net of tax	Total reclassifications, net of tax	$	1,610	$	759	$	3,898	$	2,128	Total reclassifications, net of tax	$	1,597	$	3,073	$	5,495	$	5,201

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

Note 12 — Taxes on income from continuing operations
Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020
Effective income tax rate 16.5% 50.9% 15.4% 13.8%

Three Months Ended

Nine Months Ended

September 26, 2021

September 27, 2020

September 26, 2021

September 27, 2020

Effective income tax rate

13.0%

(0.8)%

14.1%

7.8%

The effective income tax rates for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 were ~~16.5%~~13.0% and ~~15.4%~~14.1%, respectively. The effective income tax rates for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 ~~and~~reflect tax expense associated with the Respiratory business divestiture. The effective income tax rates for the three and nine months ended ~~June 28,~~September 27, 2020 reflect ~~non-deductible contingent consideration expenses recognized in connection with an increase~~non taxable charges related to a decrease in the fair value of the NeoTract and Essential Medical contingent consideration ~~liabilities. For the three~~liabilities and ~~six months ended June 27, 2021 and June 28, 2020 we recognized a~~significant net tax benefit related to share-based compensation. ~~In addition, the effective income tax rate for the three and six months ended June 28, 2020 reflects non-deductible termination benefits incurred in connection with the 2020 Restructuring program.~~

Note 13 — Commitments and contingent liabilities

Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or

~~TELEFLEX INCORPORATED~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)~~

~~(Unaudited)~~

releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S.

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At ~~June 27,~~September 26, 2021, we have recorded $1.6 million and ~~$4.9~~$5.2 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of ~~June 27,~~September 26, 2021. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years.

Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of ~~June 27,~~September 26, 2021, we have recorded accrued liabilities of ~~$0.4~~$0.7 million in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters.

As previously disclosed, in the first quarter of 2021, representatives of the selling shareholders from whom we acquired Essential Medical, Inc., filed suit on behalf of such shareholders in the Court of Chancery of the State of Delaware alleging, among other things, that we breached the merger agreement relating to the acquisition in connection with activities relating to the achievement of revenue-based milestone goals under the agreement. The suit sought money damages in the amount of $66.9 million, plus interest. During the second quarter of 2021, the parties entered into a settlement agreement, pursuant to which we paid $17.4 million to the selling shareholders, the selling shareholders released us from the claims asserted in the lawsuit as well as any remaining obligations to make milestone payments and any other obligations relating to the merger agreement, and the lawsuit was dismissed with prejudice. As a result, we have no further potential liability related to this matter.

In June 2020, we began producing documents and information in response to a Civil Investigative Demand (a “CID”) received in March 2020 by one of our subsidiaries, NeoTract, Inc. (“NeoTract”), from the U.S. Department of Justice through the United States Attorney’s Office for the Northern District of Georgia (collectively, the “DOJ”). The CID relates to the DOJ’s investigation of a single NeoTract customer, requires the production of documents and information pertaining to communications with, and certain rebate programs offered to, that customer and pertains to communications and activities occurring both prior to our acquisition of NeoTract in October 2017 and thereafter. In July 2020, the DOJ advised us that it had opened an investigation under the civil False Claims Act, 31 U.S.C. §3729, with respect to NeoTract’s operations broadly in addition to the customer investigation.

Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.

We maintain policies and procedures to promote compliance with the Anti-Kickback Statute, False Claims Acts and other applicable laws and regulations and intend to provide information sought by the government. We cannot at this time reasonably predict, however, the ultimate scope or outcome of this matter, including whether an investigation may raise other compliance issues of interest, including those beyond the scope described above or how any such issues might be resolved. We also cannot at this time reasonably estimate any potential liabilities or penalty, if any, that may arise from this matter, which could have a material adverse effect on our results of operations and financial condition.

~~Tax audits and examinations:~~ Other:~~We are routinely~~ As previously disclosed, we have been subject to ~~tax examinations~~an investigation by ~~various tax authorities.~~Chinese authorities related to a technical error regarding our country of origin designation for certain products we imported into China. Had the error not been made, we would have been obligated to make increased tariff payments in late 2018 through the first quarter of 2021. As of ~~June 27,~~March 28, 2021, we accrued the ~~most significant tax examinations~~estimated increase in ~~process were in Ireland and Germany. We may establish~~tariffs as well as related interest

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

expense for the periods in question. In addition to the tariffs and related interest, the Chinese authorities may impose a penalty for the unpaid tariffs.

As of September 26, 2021, after receiving requests for payment of the increased tariff amounts from the Chinese authorities, we remitted payment for the increased tariffs and we believe this to be the final action required to close the case. We no longer consider payment of penalties or interest to be probable, so we reversed the $3.0 million of previously accrued penalties as well as the accrued interest.

However, we have not received confirmation from the Chinese authorities that the case is closed and as a result, it remains possible that they may request payment for penalties and interest in the future. As we had indicated in our prior disclosure, we believe the range of penalties could be between 30% and 200% of the increased tariff amount or between $3 million and $20 million.

Tax audits and examinations: We are routinely subject to tax examinations by various tax authorities. As of September 26, 2021, the most significant tax examinations in process were in Ireland and Germany. We may establish reserves with respect to our uncertain tax positions, after we adjust the reserves to address developments with respect to our uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to our recorded tax liabilities, which could impact our financial results.

Note 14 — Segment information

The following tables present our segment results for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020:

Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020
Americas $ 414,785 $ 312,490 $ 790,278 $ 670,492
EMEA 157,129 131,643 298,382 287,767
Asia 80,603 67,069 144,293 120,198
OEM 60,956 55,832 114,445 119,219
Net revenues $ 713,473 $ 567,034 $ 1,347,398 $ 1,197,676
Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020
Americas $ 105,379 $ 47,539 $ 188,981 $ 188,507
EMEA 23,301 14,923 46,296 35,342
Asia 23,188 13,626 38,104 23,858
OEM 15,262 12,244 27,824 27,343
Total segment operating profit (1)
167,130 88,332 301,205 275,050
Unallocated expenses (2)
(38,510) (49,522) (69,151) (79,154)
Income from continuing operations before interest and taxes $ 128,620 $ 38,810 $ 232,054 $ 195,896


	Three Months Ended				Nine Months Ended
	September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Americas	$	417,330	$	375,040	$	1,207,608	$	1,045,532
EMEA	143,882		135,649		442,264		423,416
Asia	74,956		68,213		219,249		188,411
OEM	64,083		49,399		178,528		168,618
Net revenues	$	700,251	$	628,301	$	2,047,649	$	1,825,977


	Three Months Ended				Nine Months Ended
	September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Americas	$	112,476	$	121,760	$	301,457	$	310,267
EMEA	19,566		17,702		65,862		53,044
Asia	27,536		10,099		65,640		33,957
OEM	14,359		8,281		42,183		35,624
Total segment operating profit (1)	173,937		157,842		475,142		432,892
Unallocated expenses (2)	67,038		(25,750)		(2,113)		(104,904)
Income from continuing operations before interest and taxes	$	240,975	$	132,092	$	473,029	$	327,988

(1)Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved.

(2)Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges and gain on sale of ~~assets.~~business, as applicable.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Teleflex Incorporated (“we,” “us,” “our" and “Teleflex”) is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.

We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, particularly in Asia, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.

Divestiture

Net ~~sales~~revenues attributable to our Divested respiratory business recognized prior to the Respiratory business divestiture are included within each of our geographic segments and were ~~$29.6 million and~~ $60.7 million during the nine months ended September 26, 2021, and $29.8 million and $102.5 million for the three and ~~six~~nine months ended ~~June~~September 27, 2020, respectively. For the three and nine months ended September 27, 2021, ~~respectively, and $138.5~~we recognized $27.9 million ~~during~~in net revenues attributed to services provided to Medline in accordance with the ~~year ended December 31, 2020.~~MSTA, which are presented within our Americas reporting segment.

COVID-19 pandemic

Beginning in the first half of 2020, the challenges arising from the COVID-19 pandemic have adversely impacted our financial results, mainly as a result of a decline in demand for certain of our products, and have had an effect on various aspects of our global operations as well as our employees, contractors, suppliers, customers, freight transport providers and other business partners. Our business has been impacted by travel restrictions,

border closures and quarantines as they affect our various sites, including our 35 global manufacturing sites. We have also experienced inefficiencies in our manufacturing operations due to temporary or partial work stoppages as well as government-mandated and self-imposed restrictions placed on, and safety measures implemented at, our facilities globally. We continue to monitor the impacts to our operations. While we have not yet experienced significant disruptions in the global supply chain for our products that are in high demand, we have in some cases experienced lengthened delivery times, resulting in backorders for some of our products.

To date, our financial results were most severely impacted by the pandemic during the second quarter of 2020 due to reduced elective procedure volumes, partially offset by increased demand for products used in the treatment of

patients with COVID-19. Since the second quarter of 2020, we have experienced varying levels of continuing recovery across our product lines and geographic segments from the challenges ~~caused by~~stemming from the pandemic. We believe that the COVID-19 pandemic will continue to have an impact on our business, particularly in the near term, and that such impact would be most significant if the virus becomes more prevalent, if vaccine immunization rates do not increase and if new strains of the virus continue to emerge. As a result of the dynamic nature of the crisis, we cannot accurately predict the extent or duration of the impacts of the pandemic.

Results of Operations

As used in this discussion, "new products" are products for which commercial sales have commenced within the past 36 months, and “existing products” are products for which commercial sales commenced more than 36 months ago. Discussion of results of operations items that reference the effect of one or more acquired and/or divested businesses or assets (except as noted below with respect to acquired distributors) generally reflects the impact of the acquisitions and/or divestitures within the first 12 months following the date of the acquisition and/or divestiture. In addition to increases and decreases in the per unit selling prices of our products to our customers, our discussion of the impact of product price increases and decreases also reflects the impact on the pricing of our products resulting from the elimination of the distributor, either through acquisition or termination of the distributor, from the sales channel. All of the dollar amounts in the tables are presented in millions unless otherwise noted.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Net revenues

Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020
Net revenues $ 713.5 $ 567.0 $ 1,347.4 $ 1,197.7


	Three Months Ended				Nine Months Ended
	September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Net revenues	$	700.3	$	628.3	$	2,047.6	$	1,826.0

Net revenues for the three months ended ~~June 27,~~September 26, 2021 increased ~~$146.5~~$72.0 million, or ~~25.8%~~11.5%, compared to the prior year period, which was primarily attributable to a ~~$89.6~~$27.4 million increase in sales ~~volume~~volumes of existing products largely ~~caused by~~stemming from the impact that the COVID-19 pandemic had on the prior year, ~~$22.8~~net revenues of $17.5 million generated by the Z-Medica acquisition, a $14.9 million increase in new product sales, and to a lesser extent, favorable fluctuations in foreign currency exchange rates.

Net revenues for the nine months ended September 26, 2021 increased $221.6 million, or 12.1%, compared to the prior year period, which was primarily attributable to a $70.2 million increase in sales volume of existing products largely stemming from the impact that the COVID-19 pandemic had on the prior year, net revenues of $53.5 million generated by acquired businesses, primarily Z-Medica, $49.9 million of favorable fluctuations in foreign currency exchange rates, and, to a lesser extent, ~~net revenues generated by the Z-Medica acquisition.~~an increase in new product sales.

~~Net revenues~~Gross profit


	Three Months Ended						Nine Months Ended
	September 26, 2021			September 27, 2020			September 26, 2021			September 27, 2020
Gross profit	$	387.8		$	329.3		$	1,129.9		$	941.3
Percentage of sales	55.4		%	52.4		%	55.2		%	51.6		%

Gross margin for the ~~six~~three months ended ~~June 27,~~September 26, 2021 increased ~~$149.7 million,~~300 basis points, or ~~12.5%~~5.7%, compared to the prior year period, ~~which was~~ primarily ~~attributable~~due to ~~$43.1 million of~~benefits from cost improvement initiatives, favorable ~~fluctuations in foreign currency exchange rates, a $42.9 million increase in~~product mix, higher sales ~~volume of existing products largely caused by~~volumes partially stemming from the impact that the COVID-19 pandemic had on the prior year, price increases and ~~net revenues of $36.1 million generated~~favorable fluctuations in foreign exchange rates. The increases in gross margin was partially offset by ~~acquired businesses, primarily Z-Medica.~~increases in logistics and distribution costs.

~~Gross profit~~

Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020
Gross profit $ 397.6 $ 278.4 $ 742.1 $ 612.0
Percentage of sales 55.7 % 49.1 % 55.1 % 51.1 %

Gross margin for the ~~three~~nine months ended ~~June 27,~~September 26, 2021 increased ~~660~~360 basis points, or ~~13.4%~~7.0%, compared to the prior year period, primarily due to higher sales volumes largely ~~caused by the impact that the COVID-19 pandemic had on the prior year, benefits~~stemming from cost improvement initiatives, favorable fluctuations in foreign currency exchange rates and favorable gross profit generated by Z-Medica. The increases in gross margin were partially offset by an increase in logistics and distribution costs.

~~Gross margin for the six months ended June 27, 2021 increased 400 basis points, or 7.8%, compared to the prior year period primarily due to higher sales volumes largely caused by~~ the impact that the COVID-19 pandemic had on the prior year, benefits from cost improvement initiatives and ~~to a lesser extent, price increases and~~ favorable ~~gross profit generated by acquisitions.~~

product mix.

Selling, general and administrative


		Three Months Ended						Six Months Ended							Three Months Ended						Nine Months Ended
		June 27, 2021			June 28, 2020			June 27, 2021			June 28, 2020				September 26, 2021			September 27, 2020			September 26, 2021			September 27, 2020
Selling, general and administrative	Selling, general and administrative	$	224.2		$	191.2		$	427.3		$	339.0		Selling, general and administrative	$	205.2		$	171.7		$	632.5		$	510.7
Percentage of sales	Percentage of sales	31.4		%	33.7		%	31.7		%	28.3		%	Percentage of sales	29.3		%	27.3		%	30.9		%	28.0		%

Selling, general and administrative expenses for the three months ended ~~June 27,~~September 26, 2021 increased $33.0 million compared to the prior year period. The increase was primarily attributable to higher selling and marketing expenses, largely within our interventional urology product portfolio, higher performance related employee-benefit expenses, unfavorable fluctuations in foreign currency exchange rates and operating expenses incurred by the Z-Medica acquisition. The increases in selling, general and administrative costs were partially offset by a decrease in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities.

~~Selling, general and administrative expenses for the six months ended June 27, 2021 increased $88.3~~$33.5 million compared to the prior year period. The increase was primarily attributable to the benefit recognized in the prior year resulting from decreases in the estimated fair value of our contingent consideration liabilities ~~caused by~~stemming from the adverse impacts of the COVID-19 pandemic, higher ~~performance~~selling and marketing expenses within certain of our product portfolios and operating expenses incurred to support the Z-Medica business. The increase in selling, general and administrative expenses was partially offset by a benefit from the reversal of a contingent liability related ~~employee-benefit~~to tariffs imposed by Chinese authorities, which is described further in Note 13 to the condensed consolidated financial statements.

Selling, general and administrative expenses for the nine months ended September 26, 2021 increased $121.8 million compared to the prior year period. The increase was primarily attributable to the benefit recognized in the prior year resulting from decreases in the estimated fair value of our contingent consideration liabilities stemming from the adverse impacts of the COVID-19 pandemic, operating expenses incurred by acquired businesses, primarily Z-Medica, higher performance related employee-benefit expenses and, to a lesser extent, unfavorable fluctuations in foreign currency exchange rates.

Research and development


		Three Months Ended						Six Months Ended						Three Months Ended					Nine Months Ended
		June 27, 2021			June 28, 2020			June 27, 2021			June 28, 2020					September 26, 2021			September 27, 2020			September 26, 2021			September 27, 2020
Research and development	Research and development	$	33.3		$	29.4		$	63.2		$	56.8			Research and development	$	31.8		$	29.2		$	95.0		$	86.0
Percentage of sales	Percentage of sales	4.7		%	5.2		%	4.7		%	4.7		%		Percentage of sales	4.5		%	4.7		%	4.6		%	4.7		%

The increase in research and development expenses for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 compared to the prior year period was primarily attributable to European Union Medical Device Regulation ("EU MDR") related costs partially offset by lower project spend within certain of our product portfolios.

Restructuring and impairment charges

Respiratory divestiture plan

During the second quarter of 2021, in connection with the Respiratory business divestiture, we committed to a restructuring plan designed to separate the manufacturing operations that will be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites that will be transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023.

We estimate that we will incur aggregate pre-tax restructuring and restructuring related charges in connection with the Respiratory divestiture plan of $24 million to $30 million, of which we expect $6 million to $7 million to be incurred in 2021 and the balance to be incurred in 2022 and 2023. We estimate that substantially all of these charges will result in cash outlays, the majority of which will be made in 2022 and 2023. Additionally, we expect to incur $22 million to $28 million in aggregate capital expenditures under the plan, which are expected to be incurred mostly in 2022 and 2023.

2021 Restructuring plan

restructuring related charges, most of which are expected to be recognized in cost of sales. We expect this program will be substantially completed by the end of 2021.

We ~~expect to begin~~began realizing plan-related savings in 2021 and expect to achieve annual pre-tax savings of $13 million to $16 million once the plan is fully implemented.

Anticipated charges and pre-tax savings related to restructuring programs and other similar cost savings initiatives

In addition to the Respiratory divestiture plan, described in detail above, we have ongoing restructuring programs that include the consolidation of our manufacturing operations (referred to as our 2019, 2018 and 2014 Footprint realignment plans) and the 2021 Restructuring plan, which is also described above. We also have similar ongoing activities to relocate certain manufacturing operations within our OEM segment (the "OEM initiative") that do not meet the criteria for a restructuring program under applicable accounting guidance; nevertheless, the activities should result in cost savings (we expect only minimal costs to be incurred in connection with the OEM initiative). With respect to the restructuring programs and the OEM initiative, the table below summarizes charges incurred or estimated to be incurred and estimated annual pre-tax savings to be realized as follows: (1) with respect to charges (a) the estimated total charges that will have been incurred once the restructuring programs and OEM initiative are completed; (b) the charges incurred through December 31, 2020; and (c) the estimated charges to be incurred from January 1, 2021 through the last anticipated completion date of the restructuring programs and OEM initiative, and (2) with respect to estimated annual pre-tax savings, (a) the estimated total annual pre-tax savings to be realized once the restructuring programs and OEM initiative are completed; (b) the estimated annual pre-tax savings realized based on the progress of the restructuring programs and OEM initiative through December 31, 2020; and (c) the estimated additional annual pre-tax savings to be realized from January 1, 2021 through the last anticipated completion date of the restructuring programs and the OEM initiative.

Estimated charges and pre-tax savings are subject to change based on, among other things, the nature and timing of restructuring activities and similar activities, changes in the scope of restructuring programs and the OEM initiative, unanticipated expenditures and other developments, the effect of additional acquisitions or dispositions, and other factors that were not reflected in the assumptions made by management in previously estimating restructuring and restructuring related charges and estimated pre-tax savings. Moreover, estimated pre-tax savings constituting efficiencies with respect to increased costs that otherwise would have resulted from business acquisitions involve, among other things, assumptions regarding the cost structure and integration of businesses that previously were not administered by our management, which are subject to a particularly high degree of risk and uncertainty. It is likely that estimates of charges and pre-tax savings will change from time to time, and the table below may reflect changes from amounts previously estimated. In addition, the table below reflects the estimated charges and pre-tax savings related to our ongoing programs. Additional details, including estimated charges expected to be incurred in connection with our restructuring programs and the anticipated completion dates, are described in Note 5 to the condensed consolidated financial statements included in this report.

Pre-tax savings may be realized during, and subsequent to, the completion of the restructuring program. Pre-tax savings can also be affected by increases or decreases in sales volumes generated by the businesses impacted by the consolidation of manufacturing operations; such variations in revenues can increase or decrease pre-tax savings generated by the consolidation of manufacturing operations. For example, an increase in sales volumes generated by the impacted businesses, although likely to increase manufacturing costs, may generate additional savings with respect to costs that otherwise would have been incurred if the manufacturing operations were not consolidated.


	Ongoing restructuring programs and other similar cost savings initiatives
	Estimated Total	Actual results through December 31, 2020	Estimated Remaining
Restructuring charges - ongoing restructuring plans	$102 - $118	$89	$13 - $29
Restructuring charges - Respiratory divestiture plan	5 - 8	—	5 - 8
Total restructuring charges	107 - ~~$126~~126	$89	18 - 37

Restructuring related charges - ongoing restructuring plans	119 - 146	74	45 - 72
Restructuring related charges - Respiratory divestiture plan	19 - 22	—	19 - 22
Total restructuring related charges (1)	138 - 168	$74	64 - 94

Total charges	$245 - $294	$163	$82 - $131


OEM initiative annual pre-tax savings	$6 - $7	$2	$4 - $5
Pre-tax savings - ongoing restructuring plans (2)	81 - 94	32	49 - 62

Total annual pre-tax savings	$87 - $101	$34	$53 - $67

(1)Represents charges that are directly related to restructuring programs and principally constitute costs to transfer manufacturing

operations to existing lower-cost locations, project management costs and accelerated depreciation, as well as a charge that is expected to be imposed by a taxing authority as a result of our exit from facilities in the authority's jurisdiction. Most of these charges (other than the tax charge) are expected to be recognized as cost of goods sold.

(2)Most of the pre-tax savings are expected to result in reductions to cost of goods sold.

Restructuring and impairment charges incurred

Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020
Restructuring and impairment charges $ 11.5 $ 19.0 $ 19.5 $ 20.4


	Three Months Ended				Nine Months Ended
	September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Restructuring and impairment charges (credits)	$	1.0	$	(3.7)	$	20.5	$	16.7

Restructuring and impairment charges for the three ~~and six~~ months ended ~~June 27,~~September 26, 2021 primarily consisted of termination benefits across our various ongoing restructuring programs.

Restructuring and impairment charges for the nine months ended September 26, 2021 primarily consisted of termination benefits related to the 2021 Restructuring plan and Respiratory divestiture plan and impairment charges of $6.7 million related to our decision to abandon intellectual property and other assets, primarily associated with our respiratory product portfolio that was not transferred to Medline as part of the Respiratory business ~~divestiture,~~divestiture.

Gain on sale of business


	Three Months Ended				Nine Months Ended
	September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Gain on sale of business	$	(91.2)	$	—	$	(91.2)	$	—

During the three and ~~termination benefits~~nine months ended September 26, 2021, we recognized a gain related to the ~~2021 Restructuring plan and~~ Respiratory ~~divestiture plan.~~business divestiture. There were no such gains in the prior year periods.

Interest expense


		Three Months Ended						Six Months Ended							Three Months Ended						Nine Months Ended
		June 27, 2021			June 28, 2020			June 27, 2021			June 28, 2020				September 26, 2021			September 27, 2020			September 26, 2021			September 27, 2020
Interest expense	Interest expense	$	16.2		$	15.7		$	33.0		$	31.1		Interest expense	$	12.0		$	16.7		$	45.0		$	47.8
Average interest rate on debt	Average interest rate on debt	2.4		%	2.3		%	2.4		%	2.5		%	Average interest rate on debt	2.0		%	2.5		%	2.3		%	2.5		%

The ~~increase~~decreases in interest expense for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 compared to the prior year periods ~~was~~were primarily due to ~~an increase~~a lower average interest rate, primarily resulting from the redemption of the 4.875% Senior Notes due 2026 (the “2026 Notes”) in ~~average~~addition to decreases in interest rates associated with our variable interest rate debt ~~outstanding.~~instruments.

Loss on extinguishment of debt


	Three Months Ended				Nine Months Ended
	September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Loss on extinguishment of debt	$	—	$	—	$	13.0	$	—

On June 1, 2021, we prepaid the $400 million aggregate outstanding principal amount under the 2026 Notes. In addition to the prepayment of principal, we paid to the holders of the 2026 Notes a $9.8 million prepayment make-whole amount plus accrued and unpaid interest. We recorded the prepayment make-whole amount and a $3.2 million write-off of unamortized debt issuance costs as a loss on extinguishment of debt.

Taxes on income from continuing operations

Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020
Effective income tax rate 16.5 % 50.9 % 15.4 % 13.8 %


	Three Months Ended				Nine Months Ended
	September 26, 2021		September 27, 2020		September 26, 2021		September 27, 2020
Effective income tax rate	13.0	%	(0.8)	%	14.1	%	7.8	%

The effective income tax rates for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 ~~and~~reflect tax expense associated with the Respiratory business divestiture. The effective income tax rates for the three and nine months ended ~~June 28,~~September 27, 2020 reflect ~~non-deductible contingent consideration expenses recognized in connection with an increase~~non taxable charges related to a decrease in the fair value of the NeoTract and Essential Medical contingent consideration ~~liabilities. For the three~~liabilities and ~~six months ended June 27, 2021 and June 28, 2020 we recognized a~~significant net tax benefit related to share-based compensation. ~~In addition, the effective income tax rate for the three and six months ended June 28, 2020 reflects non-deductible termination benefits incurred in connection with the 2020 Restructuring program.~~

Segment Financial Information
Segment net revenues
Three Months Ended Six Months Ended
June 27, 2021 June 28, 2020 % Increase/(Decrease) June 27, 2021 June 28, 2020 % Increase/(Decrease)
Americas $ 414.8 $ 312.5 32.7 $ 790.3 $ 670.5 17.9
EMEA 157.1 131.6 19.4 298.3 287.8 3.7
Asia 80.6 67.1 20.2 144.3 120.2 20.0
OEM 61.0 55.8 9.2 114.5 119.2 (4.0)
Segment net revenues $ 713.5 $ 567.0 25.8 $ 1,347.4 $ 1,197.7 12.5


Segment net revenues												Segment net revenues
													Three Months Ended					Nine Months Ended
													September 26, 2021		September 27, 2020		% Increase/(Decrease)	September 26, 2021		September 27, 2020		% Increase/(Decrease)

Americas												Americas	$	417.3	$	375.0	11.3	$	1,207.6	$	1,045.6	15.5
EMEA												EMEA	143.9		135.7		6.1	442.3		423.4		4.5
Asia												Asia	75.0		68.2		9.9	219.2		188.4		16.4
OEM												OEM	64.1		49.4		29.7	178.5		168.6		5.9

Segment net revenues												Segment net revenues	$	700.3	$	628.3	11.5	$	2,047.6	$	1,826.0	12.1

Segment operating profit	Segment operating profit											Segment operating profit
		Three Months Ended					Six Months Ended						Three Months Ended					Nine Months Ended
		June 27, 2021		June 28, 2020		% Increase/(Decrease)	June 27, 2021		June 28, 2020		% Increase/(Decrease)		September 26, 2021		September 27, 2020		% Increase/(Decrease)	September 26, 2021		September 27, 2020		% Increase/(Decrease)

Americas	Americas	$	105.4	$	47.5	121.7	$	189.0	$	188.5	0.3	Americas	$	112.5	$	121.8	(7.6)	$	301.4	$	310.3	(2.8)
EMEA	EMEA	23.3		14.9		56.1	46.3		35.3		31.0	EMEA	19.6		17.7		10.5	65.9		53.0		24.2
Asia	Asia	23.2		13.6		70.2	38.1		23.9		59.7	Asia	27.5		10.1		172.7	65.6		34.0		93.3
OEM	OEM	15.2		12.3		24.6	27.8		27.4		1.8	OEM	14.4		8.2		73.4	42.2		35.6		18.4

Segment operating profit (1)	Segment operating profit (1)	$	167.1	$	88.3	89.2	$	301.2	$	275.1	9.5	Segment operating profit (1)	$	174.0	$	157.8	10.2	$	475.1	$	432.9	9.8

(1)See Note 14 to our condensed consolidated financial statements included in this report for a reconciliation of segment operating profit to our condensed consolidated income from continuing operations before interest and taxes.

Comparison of the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020

Americas

Americas net revenues for the three months ended ~~June 27,~~September 26, 2021 increased ~~$102.3~~$42.3 million, or ~~32.7%~~11.3%, compared to the prior year period, which was primarily attributable to net revenues of $15.6 million generated by the Z-Medica acquisition, a $9.9 million increase in new product sales and price increases. The increase in net revenue was also the result of sales made to Medline pursuant to the MSTA.

Americas net revenues for the nine months ended September 26, 2021 increased $162.0 million, or 15.5%, compared to the prior year period, which was primarily attributable to a ~~$73.0~~$72.9 million increase in sales volumes of

existing products largely ~~caused by~~stemming from the impact that the COVID-19 pandemic had on the prior year, ~~and~~ net revenues of ~~$14.5~~$44.8 million generated by the Z-Medica ~~acquisition.~~acquisition and, to a lesser extent, an increase in new product sales.

Americas ~~net revenues~~operating profit for the ~~six~~three and nine months ended ~~June 27,~~September 26, 2021 ~~increased $119.8~~decreased $9.3 million, or ~~17.9%~~7.6% and $8.9 million, or 2.8%, respectively, compared to the corresponding prior year period, which was primarily attributable to a $70.0 million increase in sales volumes of existing products largely caused by the impact that the COVID-19 pandemic had on the prior year and net revenues of $29.2 million generated by the Z-Medica acquisition.

Americas operating profit for the three months ended June 27, 2021 increased $57.9 million, or 121.7%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales and lower contingent consideration expense, partially offset by higher operating expenses, including expenses incurred to support higher sales, and expenses incurred by Z-Medica.

Americas operating profit for the six months ended June 27, 2021 increased $0.5 million, or 0.3%, compared to the prior year period, which was primarily attributable an increase in gross profit resulting from higher sales, partially offset by a benefit recognized in the prior year resulting from decreases in the estimated fair value of our contingent consideration liabilities ~~caused by~~stemming from the ~~adverse~~ impacts of the COVID-19 pandemic ~~higher operating expenses, including expenses incurred to support higher sales,~~ and expenses incurred by ~~Z-Medica.~~Z-Medica, partially offset by an increase in gross profit resulting from higher sales.

In July 2021, the Center for Medicare and Medicaid Services (CMS) published its proposed Physician Fee Schedule (PFS) and proposed Outpatient Prospective Payment System (OPPS) rates for calendar year 2022. The proposed rules, among other things, provide for updates with respect to the rates used to determine the reimbursement amounts received by healthcare providers across a broad range of healthcare procedures, including our UroLift System procedure. Specifically, for UroLift procedures performed in a physician office setting, the reimbursement rates outlined in the proposed PFS are 19-21% lower as compared to 2021, while the proposed reimbursement rates outlined in the OPPS for UroLift procedures performed in the hospital outpatient or ambulatory surgical center setting are 3% higher as compared to 2021. During the 60-day public comment period for the proposed rules, we ~~plan to engage~~engaged with industry associations and other key stakeholders to reiterate the benefits of the UroLift System and the importance of compensating physicians appropriately for performing procedures such as UroLift in lower cost settings, such as the physician’s office, and to advocate for reimbursement rates higher than what has been proposed. We anticipate the final rules to be published during the fourth quarter of 2021. In the event

the proposed reimbursement rates for the UroLift procedure are adopted in the final rules, we may experience an adverse effect on sales of our UroLift System to urologists performing the procedure in the office setting. From the beginning of 2016 through ~~June of~~September 2021, approximately two-thirds of Urolift procedures have been performed in a hospital outpatient or ambulatory surgical center setting with the remainder being performed in a physician office setting.

EMEA

EMEA net revenues for the three months ended ~~June 27,~~September 26, 2021 increased ~~$25.5~~$8.2 million, or ~~19.4%~~6.1%, compared to the prior year period, which was primarily attributable to ~~$13.3 million of favorable fluctuations in foreign currency~~

~~exchange rates and~~ a ~~$10.4~~$6.9 million increase in sales volumes of existing products largely ~~caused by~~stemming from the impact that the COVID-19 pandemic had on the prior ~~year.~~

~~EMEA net revenues for the six months ended June 27, 2021 increased $10.5 million, or 3.7%, compared to the prior~~ year ~~period, which was primarily attributable to $27.1~~and $3.2 million of favorable fluctuations in foreign currency exchange rates, partially offset by a ~~$20.0~~$4.5 million decrease in sales volumes attributed to the Respiratory business divestiture.

EMEA net revenues for the nine months ended September 26, 2021 increased $18.9 million, or 4.5%, compared to the prior year period, which was primarily attributable to $30.3 million of favorable fluctuations in foreign currency exchange rates, partially offset by a $13.2 million decrease in sales volumes of existing products largely ~~caused by~~stemming from the COVID-19 pandemic.

EMEA operating profit for the three months ended ~~June 27,~~September 26, 2021 increased ~~$8.4~~$1.9 million, or ~~56.1%~~10.5%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales, ~~and favorable fluctuations in foreign currency chance rates,~~ partially offset by an increase in EU MDR costs within research and development.

EMEA operating profit for the ~~six~~nine months ended ~~June 27,~~September 26, 2021 increased ~~$11.0~~$12.9 million, or ~~31.0%~~24.2%, compared to the prior year period, which was primarily attributable to favorable fluctuations in foreign currency ~~chance~~exchange rates, ~~and lower operating expenses,~~ partially offset by an increase in EU MDR costs within research and development.

Asia

Asia net revenues for the three months ended ~~June 27,~~September 26, 2021 increased ~~$13.5~~$6.8 million, or ~~20.2%~~9.9%, compared to the prior year period, which was primarily attributable to ~~$6.0~~a $5.1 million increase in sales volumes of existing products largely stemming from the impact that the COVID-19 pandemic had on the prior year, favorable fluctuations in foreign currency exchange rates and new product sales, partially offset by a decrease in sales volumes attributed to the Respiratory business divestiture.

Asia net revenues for the nine months ended September 26, 2021 increased $30.8 million, or 16.4%, compared to the prior year period, which was primarily attributable to $12.9 million of favorable fluctuations in foreign currency exchange rates, a ~~$3.6~~$10.8 million increase in sales volumes of existing products largely ~~caused by~~stemming from the impact that the COVID-19 pandemic had on the prior year and a ~~$2.5~~$7.1 million increase in new product ~~sales.~~sales,

Asia operating profit for the three and nine months ended September 26, 2021 increased $17.4 million, or 172.7%, and $31.6 million, or 93.3%, respectively, compared to the corresponding prior year period, which was

primarily attributable to an increase in gross profit resulting from higher sales, favorable fluctuations in foreign currency exchange rates and a benefit from the reversal of a contingent liability related to tariffs imposed by Chinese authorities, which is described further in Note 13 to the condensed consolidated financial statements.

OEM

OEM net revenues for the ~~six~~three months ended ~~June 27,~~September 26, 2021 increased ~~$24.1~~$14.7 million, or ~~20.0%~~29.7%, compared to the prior year period, which was primarily attributable to ~~$10.7 million of favorable fluctuations in foreign currency exchange rates,~~ a ~~$5.7~~$12.4 million increase in sales volumes of existing products largely ~~caused by~~stemming from the impact that the COVID-19 pandemic had on the prior year and a ~~$4.8~~$2.1 million increase in new product sales.

Asia operating profit for the three and six months ended June 27, 2021 increased $9.6 million, or 70.2%, and $14.2 million, or 59.7%, respectively compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales and favorable fluctuations in foreign currency exchange rates.

~~OEM~~

OEM net revenues for the ~~three~~nine months ended ~~June 27,~~September 26, 2021 increased ~~$5.2~~$9.9 million, or ~~9.2%~~5.9%, compared to the prior year period, which was primarily attributable to a ~~$2.7 million increase in sales volumes of existing products largely caused by the impact that the COVID-19 pandemic had on the prior year, a $1.5~~$4.1 million increase in new product sales, ~~and favorable fluctuations in foreign currency exchange rates.~~

OEM net revenues for the six months ended June 27, 2021 decreased $4.7 million, or 4.0%, compared to the prior year period, which was primarily attributable to a net $12.8 million decrease in sales volumes of existing products largely caused by impact of the COVID-19 pandemic, partially offset by net revenues of $4.0 million generated by the HPC acquisition and ~~$2.3~~$2.5 million of favorable fluctuations in foreign currency exchange rates.

OEM operating profit for the three months ended ~~June 27,~~September 26, 2021 increased ~~$2.9~~$6.2 million, or ~~24.6%~~73.4%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales.

OEM operating profit for the ~~six~~nine months ended ~~June 27,~~September 26, 2021 increased ~~$0.4~~$6.6 million or ~~1.8%~~18.4%. compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales and HPC acquisition costs incurred in the prior ~~period partially offset by a decrease in gross profit resulting from lower sales.~~period.

Liquidity and Capital Resources

While the potential economic impact resulting from the COVID-19 pandemic and the extent and duration of the pandemic's impact are difficult to assess or predict, the impact of the pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In consideration of the significant uncertainty created by the COVID-19 pandemic, we are continuing to assess our liquidity and anticipated capital requirements. Notwithstanding the significant uncertainty created by the COVID-19 pandemic, we believe our cash flow from operations, available cash and cash equivalents and borrowings under our revolving credit facility will enable us to fund our operating requirements, capital expenditures and debt obligations for the next 12 months and the foreseeable future. We have net cash provided by United States based operating activities as well as non-United States sources of cash available to help fund our debt service requirements in the

United States. We manage our worldwide cash requirements by monitoring the funds available among our subsidiaries and determining the extent to which we can access those funds on a cost effective basis.

In consideration of the ongoing COVID-19 pandemic, we are closely monitoring our receivables and payables. To date, we have not experienced significant payment defaults by, or identified other collectability concerns with, our customers, and we have sufficient lending commitments in place to enable us to fund our anticipated additional operating needs.

Cash Flows

Net cash provided by operating activities from continuing operations was ~~$265.1~~$450.5 million for the ~~six~~nine months ended ~~June 27,~~September 26, 2021 as compared to net cash provided by operating activities of ~~$134.0~~$241.5 million for the ~~six~~nine months ended ~~June 28,~~September 27, 2020. The ~~$131.1~~$209.0 million increase was primarily attributable to favorable operating results, lower contingent consideration payments, ~~and~~ lower payroll and benefit related payments, and $33.8 million in proceeds received as part of the initial phase of the Respiratory business divestiture attributed to performance obligations under the MSTA. The increases in operating cash flows was partially offset by ~~unfavorable changes in working capital and higher tax payments. The unfavorable impact from changes in working capital was primarily due to a net~~an increase in ~~accounts receivable resulting from higher sales.~~tax payments related to the Respiratory business divestiture.

Net cash ~~used in~~provided from investing activities from continuing operations was ~~$31.8~~$167.7 million for the ~~six~~nine months ended ~~June 27,~~September 26, 2021, ~~which~~ primarily consisted $225.9 million in proceeds from the sale of the Respiratory business divestiture, capital expenditures of ~~$36.7~~$52.1 million and net interest proceeds on swaps designated as net investment hedges of $9.3 million.

Net cash used in financing activities from continuing operations was ~~$240.7~~$500.4 million for the ~~six~~nine months ended ~~June 27,~~September 26, 2021, ~~which~~ primarily consisted of a reduction in borrowings of ~~$175.0~~$434.0 million, primarily resulting from the redemption of the $400 million ~~of 4.875% Senior~~2026 Notes, ~~due 2026 (the “2026 Notes”) partially offset by draws on our senior credit facility,~~ dividend payments of ~~$31.8~~$47.7 million and contingent consideration payments of ~~$30.5~~$31.4 million.

Borrowings

~~On July 6, 2021, which was subsequent to~~During the ~~end of our second~~third quarter of 2021, we repaid $259 million of borrowings under our revolving credit facility using funds primarily consisting of proceeds we received from the initial close of the Respiratory business divestiture.

On April 29, 2021, we issued a notice of redemption to holders of our outstanding $400 million aggregate principal amount of the 2026 Notes. Pursuant to the notice of redemption, the 2026 Notes were redeemed on June 1, 2021 (the “Redemption Date”) using borrowings under the revolving credit facility and cash on hand at a redemption price equal to 102.438% of the principal amount of the 2026 Notes plus accrued and unpaid interest up to, but not including, the Redemption Date (the “Redemption Price”). We recognized a loss on extinguishment of debt of $13.0 million as a result of the redemption of the 2026 Notes.

The indenture governing our 4.625% Senior Notes due 2027 (the “2027 Notes”) ~~contains~~and 4.25% Senior Notes due 2028 (the "2028 Notes") contain covenants that, among other things and subject to certain exceptions, limit or restrict our ability, and the ability of our subsidiaries, to create liens; consolidate, merge or dispose of certain assets; and enter into sale leaseback transactions. The 4.25% Senior Notes due 2028 (the "2028 Notes") contain covenants that, among other things, will restrict our ability and the ability of our subsidiaries to create certain liens, enter into sale lease back transactions, and merge, consolidate, sell or otherwise dispose of all or substantially all of our assets.

As of ~~June 27,~~September 26, 2021, we were in compliance with these requirements. The obligations under the Credit Agreement, the 2027 Notes and 2028 Notes are guaranteed (subject to certain exceptions) by substantially all of our material domestic subsidiaries, and the obligations under the Credit Agreement are (subject to certain exceptions and limitations) secured by a lien on substantially all of the assets owned by us and each guarantor.

Summarized Financial Information – Obligor Group

The 2026 Notes and 2027 Notes (collectively, the "Senior Notes") are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes is guaranteed, jointly and severally, by an enumerated group of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. Summarized financial information for the Parent and Guarantor Subsidiaries (collectively, the “Obligor Group”) as of

~~June 27,~~ September 26, 2021 and December 31, 2020 and for the ~~six~~nine months ended ~~June 27,~~September 26, 2021 is as follows:

Six Months Ended
June 27, 2021
Obligor Group Intercompany Obligor Group (excluding Intercompany)
Net revenue $ 937.7 $ 97.8 $ 839.9
Cost of goods sold 506.0 179.4 326.6
Gross profit 431.7 (81.6) 513.3
Income from continuing operations 82.5 (19.1) 101.6
Net income 82.4 (19.1) 101.5
June 27, 2021 December 31, 2020
Obligor Group Intercompany Obligor Group
(excluding Intercompany) Obligor Group Intercompany Obligor Group
(excluding Intercompany)
Total current assets $ 856.9 $ 67.9 $ 789.0 $ 806.9 $ 49.1 $ 757.8
Total assets 5,709.9 1,348.6 4,361.3 5,867.2 1,491.4 4,375.8
Total current liabilities 768.5 526.4 242.1 796.7 541.3 255.4
Total liabilities 3,980.5 861.9 3,118.6 4,206.0 849.6 3,356.4


	Nine Months Ended
	September 26, 2021
	Obligor Group		Intercompany		Obligor Group (excluding Intercompany)
Net revenue	$	1,434.8	$	146.7	$	1,288.1
Cost of goods sold	763.5		256.4		507.1
Gross profit	671.3		(109.7)		781.0
Income from continuing operations	85.6		(14.5)		100.1
Net income	85.2		(14.5)		99.7



	September 26, 2021						December 31, 2020
	Obligor Group		Intercompany		Obligor Group (excluding Intercompany)		Obligor Group		Intercompany		Obligor Group (excluding Intercompany)

Total current assets	$	929.1	$	104.1	$	825.0	$	806.9	$	49.1	$	757.8
Total assets	5,691.7		1,382.7		4,309.0		5,867.2		1,491.4		4,375.8
Total current liabilities	798.5		519.9		278.6		796.7		541.3		255.4
Total liabilities	3,776.9		873.7		2,903.2		4,206.0		849.6		3,356.4

The same accounting policies as described in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 are used by the Parent Company and each of its subsidiaries in connection with the summarized financial information presented above. The Intercompany column in the table above represents transactions between and among the Obligor Group and non-guarantor subsidiaries (i.e. those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes). Obligor investments in non-guarantor subsidiaries and any related activity are excluded from the financial information presented above.

Critical Accounting Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

In our Annual Report on Form 10-K for the year ended December 31, 2020, we provided disclosure regarding our critical accounting estimates, which are reflective of significant judgments and uncertainties, are important to the presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions and conditions.

New Accounting Standards

See Note 2 to the condensed consolidated financial statements included in this report for a discussion of recently issued accounting guidance, including estimated effects, if any, of adoption of the guidance on our financial statements.

Forward-Looking Statements

All statements made in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from those expressed or implied by these forward-looking statements due to a number of factors, including the adverse economic conditions associated with the COVID-19 global health pandemic and the associated financial crisis, stay-at-home and other orders, which could cause material delays and cancellations of elective procedures, curtailed or

delayed spending by customers and result in disruptions to our supply chain, closure of our facilities, delays in product launches or diversion of management and other resources to respond to the COVID-19 pandemic; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 pandemic disrupts local economies and causes economies to enter prolonged recessions; changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations of shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of enacted healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes and sovereign debt issues; difficulties in entering new markets; and general economic conditions. For a further discussion of the risks relating to our business, see Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2020. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to the information set forth in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2020.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and

procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

(b) Change in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

2930

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of ~~June 27,~~September 26, 2021 and December 31, 2020, we ~~have~~had accrued liabilities of approximately ~~$0.4~~$0.7 million and $0.3 million, respectively, in connection with these matters, representing our best estimate of the cost within the range of estimated possible loss that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding lawsuits or claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity.

Item 1A. Risk Factors

See the information set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no significant changes in risk factors for the quarter ended ~~June 27,~~September 26, 2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

3031

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this report:


Exhibit No.		Description

22.1	—	List of subsidiary guarantors and guaranteed securities (incorporated by reference to Exhibit 22 to the Company’s Form 10-Q filed on April 30, 2020).
31.1	—	Certification of Chief Executive Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
31.2	—	Certification of Chief Financial Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
32.1	—	Certification of Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	—	Certification of Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1	—	The following materials from our Quarterly Report on Form 10-Q for the quarter ended ~~June 27,~~September 26, 2021, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Cover Page; (ii) the Condensed Consolidated Statements of Income for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020; (iv) the Condensed Consolidated Balance Sheets as of ~~June 27,~~September 26,, 2021 and December 31, 2020; (v) the Condensed Consolidated Statements of Cash Flows for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020; (vi) the Condensed Consolidated Statements of Changes in Equity for the three and ~~six~~nine months ended ~~June 27,~~September 26, 2021 and ~~June 28,~~September 27, 2020; and (vii) Notes to Condensed Consolidated Financial Statements.
104.1	—	The cover page of the Company's Quarterly Report on Form 10-Q for the quarter ended ~~June 27,~~September 26, 2021, formatted in inline XBRL (included in Exhibit 101.1).

3132

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TELEFLEX INCORPORATED

By:

/s/ Liam J. Kelly

Liam J. Kelly

President and Chief Executive Officer

(Principal Executive Officer)

By:

/s/ Thomas E. Powell

Thomas E. Powell

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

Dated: ~~July 29,~~October 28, 2021

3233


Three Months Ended June 28, 2020
	Termination benefits		Other costs (1)		Total
2020 Workforce reduction plan	$	10,564	$	0	$	10,564
2019 Footprint realignment plan	323		82		405
2018 Footprint realignment plan	7,545		52		7,597
Other restructuring programs (2)	169		270		439
Restructuring charges	$	18,601	$	404	$	19,005